<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.3" xml:lang="EN" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Appl Bio Mater</journal-id><journal-id journal-id-type="iso-abbrev">ACS Appl Bio Mater</journal-id><journal-id journal-id-type="publisher-id">mt</journal-id><journal-id journal-id-type="coden">aabmcb</journal-id><journal-title-group><journal-title>ACS Applied Bio Materials</journal-title></journal-title-group><issn pub-type="epub">2576-6422</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40311033</article-id><article-id pub-id-type="pmc">PMC12093376</article-id>
<article-id pub-id-type="doi">10.1021/acsabm.5c00365</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>Development of uMUC-1 Targeted NEMO Particles
with pH-Activatable MRI Signals for Enhanced Detection of Malignant
Breast Cancer Cells</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Panchal</surname><given-names>Dhruvi
M.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Gorman</surname><given-names>Alexia R.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Martinez de la Torre</surname><given-names>Celia</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes4" ref-type="notes">#</xref><xref rid="notes5" ref-type="notes">&#x02207;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Silverman</surname><given-names>Barrick M.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Scalzo</surname><given-names>Anthony J.</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Snoderly</surname><given-names>Hunter T.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath7"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1402-413X</contrib-id><name><surname>Driesschaert</surname><given-names>Benoit</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref><xref rid="aff4" ref-type="aff">&#x02225;</xref><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath8"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2519-1603</contrib-id><name><surname>Bennewitz</surname><given-names>Margaret F.</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Department
of Chemical and Biomedical Engineering, Benjamin M. Statler College
of Engineering and Mineral Resources, <institution>West
Virginia University</institution>, Morgantown, West Virginia 26506, <country>United States</country></aff><aff id="aff2"><label>&#x02021;</label>Department
of Biology, Eberly College of Arts and Sciences, <institution>West Virginia University</institution>, Morgantown, West Virginia 26506, <country>United States</country></aff><aff id="aff3"><label>&#x000a7;</label>Department
of Pharmaceutical Sciences, School of Pharmacy, <institution>West Virginia University</institution>, Morgantown, West Virginia 26506, <country>United States</country></aff><aff id="aff4"><label>&#x02225;</label>In
Vivo Multifunctional Magnetic Resonance Center, School of Medicine, <institution>West&#x0202f;Virginia University</institution>, Morgantown, West Virginia 26506, <country>United States</country></aff><aff id="aff5"><label>&#x022a5;</label>Eugene
Bennett Department of Chemistry, Eberly College of Arts and Sciences, <institution>West Virginia&#x0202f;University</institution>, Morgantown, West Virginia 26506, <country>United States</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>margaret.bennewitz@mail.wvu.edu</email>.</corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>05</month><year>2025</year></pub-date><pub-date pub-type="collection"><day>19</day><month>05</month><year>2025</year></pub-date><volume>8</volume><issue>5</issue><fpage>4251</fpage><lpage>4261</lpage><history><date date-type="received"><day>23</day><month>02</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>04</month><year>2025</year></date><date date-type="rev-recd"><day>08</day><month>04</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mt5c00365_0007" id="ab-tgr1"/></p><p>Magnetic resonance
imaging (MRI) detects more breast cancers than
mammography due to its superior soft tissue contrast; however, it
still misdiagnoses 40% of benign tumors as malignant due to clinically
used nonspecific contrast agents (e.g., gadolinium chelates). To overcome
this limitation, we developed receptor-targeted, pH-sensitive Nano-Encapsulated
Manganese Oxide (NEMO) particles as an alternative <italic>T</italic><sub>1</sub>-weighted MRI contrast agent. A breast cancer targeting
peptide, EPPT, against underglycosylated mucin-1, promotes preferential
endocytosis of NEMO particles by malignant cells and specific activation
of the MRI signal inside low pH endosomes/lysosomes. In just 30 min,
EPPT-NEMO particles produced rapid and robust <italic>T</italic><sub>1</sub>-weighted MRI contrast inside T47D breast cancer cells that
reached &#x0223c;276% signal enhancement, which was significantly brighter
than MCF10A benign control cells (&#x0223c;57% enhancement). Mn cellular
content further confirmed peptide targeting specificity, while confocal
microscopy showed the colocalization of EPPT-NEMO particles with endosomes
and lysosomes. EPPT-NEMO particles show promise as alternative <italic>T</italic><sub>1</sub>-weighted MRI contrast agents, producing significantly
brighter signals in breast cancer cells compared to benign cells within
clinically relevant timeframes. These advancements in targeted MRI
contrast agents could lead to improved accuracy in breast cancer diagnosis
and ultimately to better patient outcomes.</p></abstract><kwd-group><kwd>magnetic resonance
imaging</kwd><kwd>manganese oxide</kwd><kwd>nanoparticles</kwd><kwd>uMUC-1</kwd><kwd>breast cancer</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>U.S. Department of Health and Human Services</institution><institution-id institution-id-type="doi">10.13039/100000054</institution-id></institution-wrap></funding-source><award-id>1R15CA274189-01A1</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>West Virginia University</institution><institution-id institution-id-type="doi">10.13039/100009455</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>U.S. Department of Health and Human Services</institution><institution-id institution-id-type="doi">10.13039/100000057</institution-id></institution-wrap></funding-source><award-id>P20 GM121322</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>mt5c00365</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>mt5c00365</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Breast cancer is the second most common
cancer worldwide and is
the fourth greatest cause of cancer-related death in the world.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> The diagnostic stage and molecular subtype greatly
impact the patient's prognosis. The 5-year survival rate decreases
from 99% for localized disease to 30% with distant metastasis.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> The earlier the tumor is diagnosed, the sooner
treatment can be applied to increase survival. Currently, mammography
is the primary screening tool that aims to promote early detection;
however, it misses 20% of breast cancers, often in young women with
dense breasts.<sup><xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref4">4</xref></sup> Moreover, 50% of healthy women
will experience a false positive diagnosis over 10 years of annual
screening, wherein a benign mass is incorrectly diagnosed as malignant.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> False positives cause anxiety, distress, and
increased medical expenses due to additional testing.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup></p><p>As an adjunct to mammography, magnetic resonance
imaging (MRI)
is used for high-risk women who have a strong family history of breast
cancer or dense breast tissue. Compared to mammography, MRI has superior
contrast to visualize structural differences within soft tissue and
detect more breast cancers.<sup><xref ref-type="bibr" rid="ref2">2</xref>,<xref ref-type="bibr" rid="ref3">3</xref></sup> MRI also produces 3D
images of the tumor and does not require X-ray radiation or breast
compression. Despite increased sensitivity, MRI still misses 5&#x02013;15%
of breast cancers<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> and misdiagnoses &#x0223c;40%
of benign masses as breast cancers<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> due
to the intravenous contrast agent currently used (e.g., gadolinium
chelates). Clinically used gadolinium (Gd) chelates are always &#x0201c;ON&#x0201d;,
creating a signal wherever the agent accumulates in the body. Moreover,
Gd chelates lack specificity<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> and enter
highly vascularized tissues of benign and malignant tumors.</p><p>In light of these challenges, there is an unmet need for alternative
MRI contrast agents that offer enhanced specificity for malignant
tumors and minimize false positive diagnoses. Manganese oxide (MnO)
nanocrystals are pH-sensitive contrast agents that can switch from
an &#x0201c;OFF&#x0201d; state to an &#x0201c;ON&#x0201d; state in acidic
environments, generating bright <italic>T</italic><sub>1</sub> MRI
contrast.<sup><xref ref-type="bibr" rid="ref9">9</xref>&#x02212;<xref ref-type="bibr" rid="ref11">11</xref></sup> At the physiological pH of the bloodstream, the particles
are intact and do not cause MRI contrast. Within the tumor extracellular
space, MnO is minimally dissociated due to the slightly acidic environment
(pH 6.5&#x02013;6.9) from lactic acid buildup. However, after cancer
cell uptake into the acidic endosomes/lysosomes (pH &#x0223c; 5), MnO
robustly dissociates into Mn<sup>2+</sup>, which coordinates with
water molecules to produce a positive MRI signal, turning &#x0201c;ON&#x0201d;
MRI contrast.<sup><xref ref-type="bibr" rid="ref10">10</xref>,<xref ref-type="bibr" rid="ref12">12</xref>&#x02212;<xref ref-type="bibr" rid="ref16">16</xref></sup> The combination of MnO&#x02019;s pH-switchability
with specific targeting of breast cancer could combat the lack of
specificity that the current Gd-based contrast agents demonstrate.</p><p>Breast cancers can be grouped into four basic subtypes depending
on the expression of the estrogen receptor (ER), progesterone receptor
(PR), and human epidermal growth factor receptor 2 (HER2): luminal
A (ER+/PR+/HER2-), luminal B (ER+/PR+/HER2+), HER2 positive (ER-/PR-/HER2+),
and basal-like or triple negative (ER-/PR-/HER2-).<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> Despite luminal A being the most prevalent (68% of cases),<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> it is poorly researched relative to other subtypes.
One reason might be due to the estrogen dependency of luminal A cancers,<sup><xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref19">19</xref></sup> rendering it difficult to be grown in animal models. The biomarkers
for subtyping (HER2, ER, PR) and others associated with breast cancer
(e.g., folate receptor) could be used to target MnO nanoparticles;
however, these biomarkers are either in the cell nucleus<sup><xref ref-type="bibr" rid="ref20">20</xref>,<xref ref-type="bibr" rid="ref21">21</xref></sup> or expressed at relatively low rates.<sup><xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref23">23</xref></sup></p><p>Mucin-1
(MUC-1) is a promising target for enhanced cancer detection,
as it is overexpressed in &#x0003e;90% of breast cancers and is prevalent
in colorectal, ovarian, pancreatic, prostate, and lung carcinomas.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> The extracellular portion of mucins consists
of around 20 to 120 or more repetitions of a 20 amino acid residue
sequence (HGVTSAPDTRPAPGSTAPPA) containing five O-linked glycosylation
sites. In normal tissue, MUC-1 is a heavily glycosylated transmembrane
protein, where carbohydrates form 50&#x02013;90% of its molecular weight,
whereas, in cancerous tissue, MUC-1 loses its polarity and is underglycosylated
(i.e., uMUC-1).<sup><xref ref-type="bibr" rid="ref24">24</xref>&#x02212;<xref ref-type="bibr" rid="ref26">26</xref></sup> The MUC-1-derived peptide sequences, including RPAPGS,
PPAHGVT, and PDTRP, are the most frequent minimal epitopes being identified.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> The PDTRP motif is the most widespread epitope
to facilitate binding with targeting peptides.<sup><xref ref-type="bibr" rid="ref28">28</xref>,<xref ref-type="bibr" rid="ref29">29</xref></sup> On normal and benign cells, PDTRP is hidden by MUC-1&#x02019;s dense
hyperglycosylation, but is revealed on cancer cells due to the truncated
glycosylation of uMUC-1.<sup><xref ref-type="bibr" rid="ref30">30</xref>&#x02212;<xref ref-type="bibr" rid="ref32">32</xref></sup> The uMUC-1 targeting peptide,
EPPT, is derived from the CDR3 <italic>V</italic><sub>h</sub> region
of the ASM2 monoclonal antibody against human epithelial cancer and
has a high affinity for uMUC-1 (<italic>K</italic><sub>d</sub> = 20
&#x003bc;M).<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> uMUC-1 targeting peptides
have enhanced cancer therapy and imaging.<sup><xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref33">33</xref>&#x02212;<xref ref-type="bibr" rid="ref37">37</xref></sup> Thus, uMUC-1 targeting is attractive to increase MRI contrast agent
specificity in breast cancer cells.</p><p>In this study, nano-, encapsulated
manganese oxide (NEMO) particles
were innovatively combined with a uMUC-1 targeting peptide for enhanced
detection of breast cancer. As uMUC-1 epitopes are only revealed in
malignancy, we hypothesized that mammary carcinoma cells would preferentially
endocytose uMUC-1-targeted EPPT-NEMO particles compared with benign
cells, generating specific MRI signals inside low pH endosomes and
lysosomes of breast cancer cells. The cellular MRI signal after EPPT-NEMO
particle labeling at different time points over 1 h was assessed to
determine the optimal time for robust <italic>T</italic><sub>1</sub> MRI signal activation. MRI studies were complemented by analysis
of internalized total Mn content per cell, particle localization within
early endosomes, late endosomes, and lysosomes of cells, and cytotoxicity.
The <italic>T</italic><sub>1</sub>-weighted MRI contrast of EPPT-NEMO
in T47D breast cancer cells significantly peaked to &#x0223c;276% signal
enhancement in just 30 min, which was significantly greater than controls
(T47D cells labeled with scrambled peptide NEMO or MCF10A benign cells
labeled with EPPT-NEMO). From 30 to 45 min, EPPT-NEMO particles continued
to generate significantly greater <italic>T</italic><sub>1</sub>-weighted
MRI contrast and intracellular Mn content in malignant T47D cells
versus those in benign MCF10A controls. EPPT-NEMO particles are a
promising alternative <italic>T</italic><sub>1</sub>-weighted MRI
contrast agent that produces a significantly brighter signal in breast
cancer cells after just 30 min of incubation, which supports clinically
relevant timeframes for signal activation.</p></sec><sec id="sec2"><title>Experimental
Section</title><sec id="sec2.1"><title>Materials</title><p>Manganese(II) acetylacetonate (Mn(II)(acac)<sub>2</sub>) (technical grade, &#x02265;97%), oleylamine (technical grade,
70%), poly(vinyl alcohol) (PVA), cell proliferation reagent WST-1,
and human IgG were purchased from Sigma-Aldrich. Dibenzyl ether (&#x02265;99%,
Acros Organics), hexane (&#x02265;98.5%, Macron Fine Chemicals), dichloromethane
(99.5%, BDH Chemicals), copper(II) acetate monohydrate (98%, extra
pure, Acros Organics), tris((1-benzyl-4-triazolyl)methyl)amine (TBTA)
(97+%, Alfa Aesar), sodium ascorbate (99%, Alfa Aesar), manganese(II)
chloride tetrahydrate (98&#x02013;101% ACS), Dulbecco&#x02019;s phosphate-buffered
saline (PBS), RPMI-1640 media, fetal bovine serum (FBS), penicillin-streptomycin
(Corning), formaldehyde (16% Ultra-Pure EM grade, Polysciences Inc.),
sodium citrate dihydrate (BDH Chemicals), agarose, and citric acid
were bought from VWR (VWR Chemicals). MEGM Mammary Epithelial Cell
Growth Medium BulletKit was obtained from Lonza. Carboxylic acid-terminated,
50:50 poly(D,<sc>l</sc>-lactide-<italic>co</italic>-glycolide) (PLGA)
(viscosity: 0.55&#x02013;0.75 dL/g) was obtained from LACTEL Absorbable
Polymers. PLGA (35 kDa)&#x02013;PEG (2 kDa)&#x02013;alkyne (ALK) was
obtained from Nanosoft Polymers. Hydrochloric acid (HCl) TraceMetal
grade was acquired from Fisher Scientific. Cy5 fluorophore was obtained
from APExBIO. Pierce quantitative fluorometric peptide assay, Hoechst
33342, and CellLight Fluorescent Protein Labeling BacMam 2.0 kits
for early endosome (RFP, red-fluorescence tag), late endosome, and
lysosome (GFP, green-fluorescence tag) were purchased from Thermo
Fisher. Antibodies CD227 and SM3 were obtained from BioLegend and
Santa Cruz Technologies, respectively. Ethanol (Decon Laboratories)
was obtained internally from West Virginia University&#x02019;s Environmental
Health and Safety Services.</p></sec><sec id="sec2.2"><title>Cell Culture</title><p>MCF10A human nontumorigenic
epithelial
cells (benign fibrocystic disease) and T47D human luminal A breast
cancer cells were a kind gift from Dr. Elena Pugacheva. All cells
were cultured in a humidified incubator at 37 &#x000b0;C with 5% CO<sub>2</sub>. MCF10A cells were cultured in MEGM growth medium supplemented
with 10% FBS, 1% penicillin-streptomycin, bovine pituitary extract,
hydrocortisone, human epidermal growth factor, insulin, and gentamicin/amphotericin-B.
T47D were cultured in RPMI-1640 medium supplemented with 10% FBS,
1% penicillin-streptomycin, 10 mM HEPES, 1 mM sodium pyruvate, and
4500 mg/L glucose.</p></sec><sec id="sec2.3"><title>Synthesis of MnO Cores and NEMO Particles</title><p>MnO cores
were synthesized and characterized according to previously optimized
methods by thermal decomposition of Mn(II)(acac)<sub>2</sub> (1.51
g) with oleylamine (10 mL) and dibenzyl ether (50 mL) at 280 &#x000b0;C
for 30 min with a ramping rate of 10 &#x000b0;C/min.<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> Using a single oil-in-water emulsion, 50 mg MnO cores were
encapsulated within 100 mg of PLGA with 2.5% w/w PLGA&#x02013;PEG-ALK
with dichloromethane as the organic solvent and 10% PVA as the stabilizer;
blank particles were synthesized with no MnO cores.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> For confocal microscopy, Cy5 dye (500 &#x003bc;L of 1 mg/mL)
was added with MnO cores as the fluorescent tag.</p></sec><sec id="sec2.4"><title>uMUC-1 Peptide
Attachment to NEMO Particles</title><p>The uMUC-1
tumor-specific peptide EPPT (2-azidoacetic acid-YCAREPPTRTFAYWG) and
its scrambled peptide version (2-azidoacetic acid-PRYCGWTEARATPYF)
were obtained from AnaSpec (&#x02265;95% by HPLC). Click-chemistry
was used to form a covalent bond between the terminal azide group
on the peptide and the alkyne group on the PLGA&#x02013;PEG NEMO particles.
Briefly, &#x0223c;30 mg of NEMO particles or blank particles were mixed
with &#x0223c;70 &#x003bc;g of ligand (TBTA), &#x0223c;25 &#x003bc;g of
copper(II) acetate monohydrate, &#x0223c;7 pmol of the uMUC-1 targeting
peptide or scrambled peptide, and deionized water in a 50 mL Falcon
tube. After mixing with a bath sonicator and vortex, the Falcon tube
was deoxygenated by bubbling argon for 15 min. To reduce copper(II)
to copper(I), 0.1 mL of sodium ascorbate stock solution (5.4 mM) was
added to initiate the click chemistry reaction. The solution was mixed
overnight on a stir plate under inert conditions. Conjugated particles
were washed with deionized water (3 times at 4255 RCF, 2 times at
1734 RCF), aliquoted, and stored at &#x02212;80 &#x000b0;C.</p></sec><sec id="sec2.5"><title>Tumor-Targeted
NEMO Particle Physical and Chemical Characterization</title><p>The
morphology of uMUC-1 conjugated NEMO particles (EPPT-NEMO)
was obtained via scanning electron microscopy (SEM) with a Hitachi
Scanning Electron Microscope at 5 kV. The hydrodynamic particle size
was measured using a Nanosight NS300 (Malvern Instruments). Using
the Zetasizer Nano ZS (Malvern Instruments), zeta potential (&#x003b6;-potential)
was measured of conjugated nanoparticles suspended in deionized water;
the hydrodynamic size of the particles before and after a 24 h incubation
in PBS or RPMI 1640 media supplemented with 10% FBS was measured to
assess stability in physiological conditions. Fourier transform infrared
spectroscopy (FTIR) of EPPT-NEMO particles evaluated the surface chemistry
using a DIGILAB FTS 7000 FTIR spectrometer (PIKE technologies) equipped
with a GladiATR attenuated total reflectance module.</p></sec><sec id="sec2.6"><title>Mn Loading
and pH-Dependent NEMO Particle Controlled Release</title><p>Mn loading
of EPPT-NEMO particles was calculated by digesting &#x0223c;2
mg of particles in 150 &#x003bc;L of HCl. After complete digestion,
Mn content was analyzed under EPA Method 200.8 Revision 5.4 on an
inductively coupled plasma-mass spectrometer (ICP-MS) (PerkinElmer
NexION 2000 ICP Mass Spectrometer). Mn<sup>2+</sup> controlled release
at different pH levels over 24 h was performed as previously described.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> Briefly, 5 mg of particles were suspended in
1 mL of PBS pH 7.4 (physiological pH), 20 mM citrate buffer pH 6.5
(tumor microenvironment pH), or 20 mM citrate buffer pH 5 (endosome/lysosome
pH). Suspensions were incubated at 37 &#x000b0;C with slow rotation in
a hybridization oven. After 1, 2, 4, 8, and 24 h, supernatants were
collected at 9391 RCF and assessed for Mn<sup>2+</sup> release by
inductively coupled plasma-optical emission spectrometry (ICP-OES)
analysis (Agilent 720 ICP-OES).</p></sec><sec id="sec2.7"><title>MRI Signal of Intact and
Digested NEMO Particles</title><p>Samples
collected from Mn<sup>2+</sup> controlled release after 1 h were diluted
100-fold and analyzed for MRI properties on a 1.0 T Bruker ICON MRI.
The longitudinal relaxation rate, or <italic>R</italic><sub>1</sub>, was measured from MRI scans acquired using a RARE sequence (TE
= 10.68 ms, TR = 25.6 to 12,800 ms, resolution = 234 &#x003bc;m). Images
were evaluated with MicroDicom, and data were fitted to follow the <italic>R</italic><sub>1</sub> longitudinal relaxation equation (<xref rid="eq1" ref-type="disp-formula">eq <xref rid="eq1" ref-type="disp-formula">1</xref></xref> below) with MATLAB:<disp-formula id="eq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mt5c00365_m001" position="anchor"/><label>1</label></disp-formula>where <italic>M</italic><sub><italic>z</italic></sub> is the longitudinal magnetization aligned
along the <italic>z</italic>-axis at time <italic>t</italic>, and <italic>M</italic><sub>0</sub> is the magnetization at equilibrium.</p><p>Additionally, intact particles suspended in 0.5% agarose and HCl-digested
particles were imaged at different concentrations of Mn (0 to 2.2
mM for intact particles and 0 to 0.8 mM for digested particles) following
the same protocol as above. Data were plotted and fitted to follow <xref rid="eq2" ref-type="disp-formula">eq <xref rid="eq2" ref-type="disp-formula">2</xref></xref> to calculate the <italic>T</italic><sub>1</sub>-weighted relaxivity (<italic>r</italic><sub>1</sub>) properties of the particles:<disp-formula id="eq2"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mt5c00365_m002" position="anchor"/><label>2</label></disp-formula>where <italic>R</italic><sub>0</sub> is the relaxation rate when no Mn is present, and [Mn] is
the concentration of manganese in mM.</p></sec><sec id="sec2.8"><title>uMUC-1 Peptide Attachment
Characterization</title><p>Qualitative
characterization of EPPT peptide attachment was performed with X-ray
photoelectron spectroscopy (XPS) using a PHI VersaProbe 5000 Scanning
X-ray Photoelectron Spectrometer (ULVAC-PHI); XPS evaluated EPPT-conjugated
NEMO particles having a higher peptide content for proof-of-concept.
High-resolution nitrogen scans were acquired with a pass energy of
23.5 eV and an energy step of 0.1 eV. Quantitative characterization
of the attached peptide density to NEMO particles was performed using
the Pierce Quantitative Fluorometric Peptide Assay as per the manufacturer&#x02019;s
instructions. The unknown concentration of EPPT peptide present on
NEMO particles post-click chemistry versus pre-click chemistry (control)
was determined based on the standard curve of <italic>Final Standard
Concentration for Individual Peptides</italic> as provided in the
manufacturer&#x02019;s protocol. Hydrodynamic size and particle concentration
(Malvern NanoSight NS300) were obtained and <xref rid="eq3" ref-type="disp-formula">eq <xref rid="eq3" ref-type="disp-formula">3</xref></xref> was used to calculate peptide density:<disp-formula id="eq3"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mt5c00365_m003" position="anchor"/><label>3</label></disp-formula>where [peptide] is the concentration
of peptide calculated from the standard curve and Avogadro&#x02019;s
number; [NEMO particles] is the concentration of nanoparticles found
from Nanoparticle Tracking Analysis (NanoSight, NS300, Malvern Instruments),
and SA<sub>NEMO</sub> is the NEMO particle surface area calculated
from the hydrodynamic size.</p></sec><sec id="sec2.9"><title>Flow Cytometry of uMUC-1 Cell Expression</title><p>Cell suspensions
containing 1 &#x000d7; 10<sup>5</sup> MCF10A or T47D cells were incubated
with human IgG on ice for 30 min and then washed twice with PBS. To
assess MUC-1 and uMUC-1 expression, cells were incubated with PE-conjugated
monoclonal antibodies CD227 (1:100 dilution) or SM3 (1:200 dilution),
respectively, on ice for 30 min. For unlabeled cells, no antibody
was used. Cells were washed three times with PBS, fixed with 0.4%
formaldehyde overnight, and analyzed using a BD LSRFortessa with a
561 nm Sapphire laser.</p></sec><sec id="sec2.10"><title>In Vitro NEMO Particle Cytotoxicity</title><p>Cells were plated
and incubated overnight at 37 &#x000b0;C, and fresh media containing
different concentrations of EPPT-NEMO particles ([Mn] = 0.81, 1.63,
3.25, 6.50, and 13.00 &#x003bc;g/mL) were added. Cells incubated with
media served as negative controls. Cell viability was measured using
the WST assay according to the manufacturer&#x02019;s instructions
after 1 and 24 h of exposure.</p></sec><sec id="sec2.11"><title>MRI Cell Labeling with
NEMO Particles</title><p>Cells were plated
and grown to confluency at 37 &#x000b0;C, and fresh media was added with
or without EPPT-NEMO particles or scrambled peptide conjugated NEMO
particles at a dose of [Mn] = 6.5 &#x003bc;g/mL; peptide conjugated
blank particles were also added as an additional control. After varying
exposure times (15, 30, 45, and 60 min), media in contact with cells
was collected and cells were washed three times with PBS to remove
any additional uninternalized particles. Cells were detached, counted,
pelleted in PBS, and assessed for MRI signal at 1.0 T. The collected
media was centrifuged to pellet down intact NEMO particles, and the
supernatant was analyzed for MRI signal at 1.0 T.</p><p>Cell pellets
in PBS were imaged coronally, and collected media were imaged axially
in 0.65 mL microcentrifuge tubes following similar protocols as above
(RARE sequence, TE = 10.68 ms, TR = 25.6 to 6400 ms (cells) and 25.6
to 12,800 ms (media), resolution = 234 &#x003bc;m). Data were fitted
using <xref rid="eq1" ref-type="disp-formula">eq <xref rid="eq1" ref-type="disp-formula">1</xref></xref> to calculate <italic>R</italic><sub>1</sub> of the NEMO particle-labeled and unlabeled
(control) cells and media. The percent change in relaxation rate (%&#x00394;<italic>R</italic><sub>1</sub>) for cells and media was calculated using <xref rid="eq4" ref-type="disp-formula">eq <xref rid="eq4" ref-type="disp-formula">4</xref></xref>:<disp-formula id="eq4"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mt5c00365_m004" position="anchor"/><label>4</label></disp-formula>where <italic>R</italic><sub>1<italic>,</italic>labeled</sub> is the longitudinal relaxation rate
of cells and media labeled with NEMO particles, and <italic>R</italic><sub>1<italic>,</italic>control</sub> is the <italic>R</italic><sub>1</sub> of unlabeled cells and media unexposed to particles. After
imaging, cell pellets were digested with 150 &#x003bc;L of HCl and analyzed
with ICP-MS to obtain the total Mn content per cell.</p></sec><sec id="sec2.12"><title>Confocal Microscopy
of NEMO Particle-Labeled Cells</title><p>Cells were plated in 8-well
chamber slides and incubated at 37 &#x000b0;C
overnight to allow for attachment. Cells were then stained with either
Rab5a-RFP to visualize early endosomes, Rab7a-GFP to visualize late
endosomes, or Lamp-1-GFP to visualize lysosomes using the CellLight
fluorescent protein labeling kit according to the manufacturer&#x02019;s
instructions. Once the organelles were stained, cells were dosed with
fresh media containing Cy5-labeled EPPT-NEMO particles or Cy5-labeled
scrambled peptide-conjugated NEMO particles (control) at [Mn] = 6.5
&#x003bc;g/mL. After 15, 30, or 45 min of incubation at 37 &#x000b0;C,
cells were washed three times with PBS to remove uninternalized NEMO
particles before fixing with 4% formaldehyde and staining nuclei with
Hoechst 33342 for 20 min at room temperature. Three fields of view
were collected per chamber slide (<italic>n</italic> = 3 slides per
group) on an inverted Nikon A1R confocal microscope with an oil 40x
objective with the following lasers: 405 nm (Hoechst 33342, nuclei),
488 nm (GFP, late endosomes or lysosomes), 555 nm (RFP, early endosomes),
and 640 nm (Cy5, NEMO particles).</p></sec><sec id="sec2.13"><title>Image Analysis</title><p>Confocal images were subsequently processed
using the FIJI software. After splitting the channels, the brightness/contrast
of organelles (RFP or GFP) was adjusted to subtract the background.
The adjusted brightness/contrast was then propagated to all channels.
After processing the images, colocalization analysis of NEMO particles
with endosomes and lysosomes was conducted using FIJI. The channels
for organelles (red or green) and NEMO particles (pseudocolored yellow)
were merged to form an RGB image. Thresholding was adjusted based
on the overlap region between red and yellow for early endosomes or
an overlap between green and yellow for late endosomes and lysosomes.
The area of NEMO particles colocalized with the respective organelle
(CA<sub>NEMO</sub>) and the total area of cells and particles (TA)
in the image were obtained. The percent colocalization was calculated
based on <xref rid="eq5" ref-type="disp-formula">eq <xref rid="eq5" ref-type="disp-formula">5</xref></xref>:<disp-formula id="eq5"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mt5c00365_m005" position="anchor"/><label>5</label></disp-formula></p></sec><sec id="sec2.14"><title>Statistical Analysis</title><p>All statistical analyses were
performed in GraphPad Prism 10.4.1. Statistical analysis of pH-dependent
NEMO particle controlled release was done by performing two-way ANOVA
with Holm-&#x00160;&#x000ed;d&#x000e1;k correction. Statistical analysis
of the in vitro NEMO cytotoxicity study was performed using one-way
ANOVA with Dunnett&#x02019;s correction against the unlabeled control
group. All other statistical analyses were done by performing two-way
ANOVA with Tukey&#x02019;s correction. All experiments were performed
in at least triplicate. <italic>p</italic>-values &#x0003c;0.05 were considered
significant.</p></sec></sec><sec id="sec3"><title>Results and Discussion</title><p>Synthesized
MnO and NEMO particles presented similar characteristics
to the work previously presented, where &#x0223c;19 nm MnO cores were
successfully encapsulated in PLGA&#x02013;PEG polymer, creating spherical
particles of 166 &#x000b1; 9 nm (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A).<sup><xref ref-type="bibr" rid="ref38">38</xref>,<xref ref-type="bibr" rid="ref39">39</xref></sup> Then, the novel combination of
the tumor-targeting peptide, EPPT, against uMUC-1 and pH-responsive
NEMO particles was created via click chemistry. During the reaction,
the azide-termination on the peptide reacted with the alkyne-termination
from the PLGA&#x02013;PEG shell, forming a triazole bond. EPPT-NEMO
particles were characterized through sizing of NEMO pre- and post-peptide
attachment, quantification of attached peptide, <italic>T</italic><sub>1</sub> MRI properties, Mn loading, controlled release, chemistry,
assessment of morphology, and stability (<xref rid="fig1" ref-type="fig">Figures <xref rid="fig1" ref-type="fig">1</xref></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00365/suppl_file/mt5c00365_si_001.pdf">S1</ext-link>, <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>).</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Sizing and MRI properties
of EPPT-NEMO particles. (A) Hydrodynamic
size of EPPT-NEMO particles pre- (black line) and post (red line)
peptide attachment. (B) <italic>T</italic><sub>1</sub>-weighted <italic>r</italic><sub>1</sub> properties of intact EPPT-NEMO particles suspended
in 0.5% agarose (black) or digested in HCl (red). (C) Cumulative release
of Mn<sup>2+</sup> from EPPT-NEMO particles over 24 h after incubation
at pH 7.4 (dotted line), pH 6.5 (dashed line), and pH 5 (solid line).
Note that max Mn<sup>2+</sup> release occurred rapidly at pH 5 mimicking
endosomes/lysosomes to produce the brightest <italic>T</italic><sub>1</sub> MRI contrast after 1 h (top circle in the image to the right).
Error bars are standard deviation. *** <italic>p</italic> &#x02264;
0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mt5c00365_0001" id="gr1" position="float"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Properties of uMUC-1
Targeted NEMO
Particles (EPPT-NEMO)</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">property</th><th style="border:none;" align="center">value</th></tr></thead><tbody><tr><td style="border:none;" align="left">average mean&#x000a0;&#x000b1;&#x000a0;std</td><td style="border:none;" align="left">166 &#x000b1; 9 nm</td></tr><tr><td style="border:none;" align="left">&#x003b6;-potential</td><td style="border:none;" align="left">&#x02013;18.4 &#x000b1; 0.6 mV</td></tr><tr><td style="border:none;" align="left">Mn loading capacity</td><td style="border:none;" align="left">33%</td></tr><tr><td style="border:none;" align="left">peptide density</td><td style="border:none;" align="left">8&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02013;2</sup>&#x000a0;peptides/nm<sup>2</sup></td></tr></tbody></table></table-wrap><p>XPS was first performed
to verify the presence of the peptide qualitatively
by observing the increase in nitrogen levels before and after attachment
due to the presence of nitrogen in the amino acids that form the peptide
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00365/suppl_file/mt5c00365_si_001.pdf">Figure S1D</ext-link>). However, one of the limitations
of this technique is the inability to precisely quantify the number
of peptide chains per particle or peptide density, as it is not possible
to create a standard curve to calculate concentration. For this purpose,
the Pierce quantitative fluorometric peptide assay (Thermo Fisher)
was used to determine the peptide density attached to NEMO particles,
which was measured to be 8 &#x000d7; 10<sup>&#x02013;2</sup> peptides/nm<sup>2</sup>. The peptide density achieved was on par with other tumor-targeted
nanoparticles conjugated with similar peptide sequences.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup></p><p>For physical and chemical characterization,
conjugated particles
presented a spherical morphology, size, and &#x003b6;-potential that
would maximize cell uptake and also facilitate delivery to tumors
when transitioned to in vivo studies.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> Additionally, the ability of this novel contrast agent to switch
from an &#x0201c;OFF&#x0201d; state into an &#x0201c;ON&#x0201d; state
was observed at pH 5, as MnO required acidic environments to dissociate
into Mn<sup>2+</sup> and create a robust MRI signal (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>C).<sup><xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref10">10</xref></sup> This
switchability is marked by a &#x0223c;23-fold increase in their relaxivity, <italic>r</italic><sub>1</sub>, transitioning from 0.29 mM<sup>&#x02013;1</sup> s<sup>&#x02013;1</sup> (intact particles) to 6.6 mM<sup>&#x02013;1</sup> s<sup>&#x02013;1</sup> (fully digested particles), as shown in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>B. Clinically used
Gd-based contrast agents possess an <italic>r</italic><sub>1</sub> range of 3.5 to 3.8 mM<sup>&#x02013;1</sup> s<sup>&#x02013;1</sup>.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> Therefore, the stronger signal from
Mn<sup>2+</sup> released could assist in detecting smaller tumors.</p><p>To test our hypothesis of EPPT-NEMO being more specific toward
breast cancer cells (uMUC-1+) than benign mammary cells (uMUC-1-),
cellular uptake studies were performed. First, the uMUC-1 expression
was confirmed in human benign and mammary carcinoma cell lines. Two
different antibodies, CD227 and SM3, that bind to two separate epitopes
of the MUC-1 amino acid sequence were used to explore the cellular
expression levels of heavily glycosylated MUC-1 (CD227) compared to
underglycosylated MUC-1 (SM3) by flow cytometry (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A). The two human cell lines
used were MCF10A, a nontumorigenic epithelial cell line as the control,
and T47D, a luminal A breast cancer cell line. <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>B shows how the control cell line, MCF10A,
expressed high levels of MUC-1 (85%) but minimal levels of uMUC-1
(8%). On the other hand, the breast cancer cell line had high levels
of MUC-1 (98%) and uMUC-1 (85%). These results were expected since
it has been previously reported that noncancerous cell lines present
high levels of O-glycosylation on the variable number of the tandem
repeats region, which will allow CD227 antibody binding but block
SM3 antibody attachment due to the inaccessibility of PDTRP. In contrast,
these sugar chains are lost in cancerous cells to expose the protein
backbone, allowing the SM3 antibody to bind specifically to uMUC-1.<sup><xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref42">42</xref>,<xref ref-type="bibr" rid="ref43">43</xref></sup> As the attached uMUC-1 targeting peptide, EPPT, on the NEMO particles
binds to the same epitope as the SM3 antibody, it was hypothesized
that the EPPT conjugated particles would enable differentiation between
noncancerous versus cancerous cell lines due to their distinct uMUC-1
expression levels and promote subsequent differential NEMO particle
uptake and MRI signal generation.</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Schematic of MUC-1 glycoprotein and expression
of MUC-1 and uMUC-1
on benign versus malignant human mammary cells. (A) VNTR segment of
MUC-1 with its O-glycosylations (orange circles). The PDTRP epitope
is only visible with underglycosylation, as in breast cancer. (B)
Expression of MUC-1 and uMUC-1 on benign MCF10A and malignant T47D
cells were analyzed by flow cytometry. Unlabeled cells are colored
black; cells labeled with CD227 or SM3 antibodies are represented
in red. While the control cell line MCF10A showed a high level of
MUC-1 expression, it did not express the tumor biomarker, uMUC-1.
Meanwhile, T47D demonstrated high levels of both MUC-1 and uMUC-1
expression.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mt5c00365_0002" id="gr2" position="float"/></fig><p>The cytotoxicity of EPPT-NEMO
particles was assessed by the WST
assay (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>) after
1 and 24 h to determine the safest dose for cellular uptake studies.
Cell viability was evaluated at 1 h to determine any toxicity associated
with the cell labeling times used for MRI and confocal studies. As
particle concentration increased, cell viability decreased to a minimum
of &#x0223c;75% at the highest dose of [Mn] = 13.00 &#x003bc;g/mL in
both cell lines at 1 and 24 h. From [Mn] = 0.81 to 6.5 &#x003bc;g/mL,
cells exposed to EPPT-NEMO had a high viability of &#x0003e;85%. Based
on
this data, the highest safe dose of [Mn] = 6.5 &#x003bc;g/mL was chosen
to maximize the MRI signal for the cellular uptake studies.</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>In vitro viability
of human mammary cells exposed to EPPT-NEMO
particles for 1 and 24 h. WST assay results of EPPT-NEMO particle
exposure to (A) MCF10A for 1 h, (B) MCF10A for 24 h, (C) T47D for
1 h, and (D) T47D for 24 h. The maximum cytotoxicity was detected
at the highest dose [Mn] = 13.00 &#x003bc;g/mL for both the control
and tumorigenic cell line. Cell viability for all Mn doses were normalized
to control (cells labeled with media). Statistics are shown for any
significant reductions in viability between each Mn dose and the unlabeled
control. Error bars are standard deviation. * <italic>p</italic> &#x02264;
0.05, ** <italic>p</italic> &#x02264; 0.01, *** <italic>p</italic> &#x02264;
0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mt5c00365_0003" id="gr3" position="float"/></fig><p>Cell uptake studies were conducted
where the cells were exposed
to [Mn] = 6.5 &#x003bc;g/mL EPPT-NEMO or scrambled peptide-NEMO to determine
the MRI signal of the labeled cells and media over 60 min. We hypothesized
that the uMUC-1 targeting of the EPPT-NEMO particles would facilitate
increased cell uptake, intracellular MnO dissolution to Mn<sup>2+</sup>, and a higher MRI signal over 60 min for the malignant T47D cells.
The control groups, i.e., MCF10A benign cells with EPPT-NEMO or MCF10A
cells and T47D breast cancer cells with scrambled peptide-NEMO, would
have lower MRI signal due to the lack of uMUC-1 cellular expression
or lack of EPPT nanoparticle targeting, respectively. As shown in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>A,B (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00365/suppl_file/mt5c00365_si_001.pdf">Tables S1 and S2</ext-link> for numerical values), the MRI
signal of EPPT-NEMO in T47D cells significantly peaked to &#x0223c;276%
signal enhancement at 30 min, which was significantly greater than
that of MCF10A cells labeled with EPPT-NEMO (&#x0223c;57%), T47D cells
labeled with scrambled-peptide NEMO (&#x0223c;123%), and MCF10A cells
labeled with scrambled-peptide NEMO (&#x0223c;160%). At 45 min, the
MRI signal change (%&#x00394;<italic>R</italic><sub>1</sub>) decreased
to &#x0223c;150% enhancement for T47D cells + EPPT-NEMO; however, the
MRI signal remained significantly higher than control MCF10A cells
labeled with EPPT-NEMO. To our surprise, the MRI signal of T47D cells
incubated with scrambled-peptide-NEMO increased by &#x0223c;6.5-fold
by 30 min and plateaued for the rest of the time points. By 60 min,
the change in MRI signal in T47D cells labeled with EPPT-NEMO and
scrambled peptide NEMO was nearly identical.</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p><italic>T</italic><sub>1</sub>-weighted MRI scans, quantification
of MRI signal change, and Mn content of benign and malignant mammary
cells labeled with NEMO particles over 60 min. (A) Representative <italic>T</italic><sub>1</sub>-weighted MRI scans of MCF10A and T47D cell
pellets labeled with media only (control) or [Mn] = 6.5 &#x003bc;g/mL
of NEMO particles over 60 min. (B) Quantification of change in relaxation
rate &#x00394;<italic>R</italic><sub>1</sub> for MCF10A versus T47D
cells. The enhancement in <italic>T</italic><sub>1</sub>-weighted
MRI signal of T47D cells labeled with EPPT-NEMO reached its peak at
30 min and then decreased. From 30 to 45 min, %&#x00394;<italic>R</italic><sub>1</sub> was significantly greater for T47D cells labeled with
EPPT-NEMO compared with MCF10A cells. MRI signal enhancement of scrambled
peptide conjugated blank particles was demonstrated to be &#x0223c;33%
(black dotted line), raising the baseline MRI signal of scrambled
peptide groups. (C) ICP-MS quantification of Mn cell content. T47D
cells labeled with EPPT-NEMO had significantly greater internalized
Mn compared to both control groups from 30 to 60 min. Error bars are
standard deviation. ** <italic>p</italic> &#x02264; 0.01, *** <italic>p</italic> &#x02264; 0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mt5c00365_0004" id="gr4" position="float"/></fig><p>To gain further insight into the MRI trends, the Mn content of
the labeled cells was measured with ICP-MS (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>C). Similar to the pattern observed on MRI,
T47D cells labeled with EPPT-NEMO had the highest intracellular Mn
content at 30 min, which significantly decreased at 45 min, indicating
some exocytosis of the internalized particles or released Mn<sup>2+</sup> ions. The intracellular Mn content of the control groups (MCF10A
cells + EPPT-NEMO, T47D cells + scrambled-peptide NEMO, and MCF10A
cells + scrambled-peptide NEMO) was significantly lower than T47D
cells labeled with EPPT-NEMO from 30 to 60 min, demonstrating the
specificity of the uMUC-1 peptide targeting.</p><p>By comparing the
MRI signal versus Mn cellular content (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>B,C), it is evident
that the higher Mn content in T47D cells labeled with EPPT-NEMO does
not necessarily translate to a higher MRI signal at later time points.
Based on the ICP-MS results, Mn cellular content remains high in T47D
cells labeled with EPPT-NEMO from 30 to 60 min, but the observed <italic>T</italic><sub>1</sub> MRI signal enhancement markedly decreased
for 45 and 60 min post-labeling. We hypothesize that this reduction
in %&#x00394;<italic>R</italic><sub>1</sub> can be attributed to some
quenching of Mn<sup>2+</sup> due to higher conversion of MnO to Mn<sup>2+</sup> at later time points, coupled with the confined endosomal
space limiting water relaxation and the increased <italic>T</italic><sub>2</sub> shortening effects with higher Mn<sup>2+</sup> concentrations,
which is consistent with published literature.<sup><xref ref-type="bibr" rid="ref44">44</xref>&#x02212;<xref ref-type="bibr" rid="ref46">46</xref></sup></p><p>The %&#x00394;<italic>R</italic><sub>1</sub> of MCF10A cells and
T47D cells labeled with scrambled peptide-NEMO (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>B) was also as high as 160% despite the low
Mn intracellular content (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>C). The observed increase in MRI signal enhancement
in scrambled peptide controls compared to those in EPPT-NEMO particles
may be attributed to differential quenching of Mn<sup>2+</sup>. As
stated above, the EPPT peptide demonstrates a higher uptake of NEMO
particles in malignant T47D cells, leading to an increased conversion
of MnO to Mn<sup>2+</sup>, which is hypothesized to result in <italic>T</italic><sub>1</sub> MRI signal quenching at later time points.
Since cells labeled by scrambled peptide NEMO did endocytose low levels
of Mn according to ICP-MS, they would experience some <italic>T</italic><sub>1</sub> MRI signal enhancement without quenching.</p><p>Alternatively,
it may be possible that the scrambled peptide activates
certain signaling pathways, which results in a higher MRI signal,
even though the uptake is low in both T47D and MCF10A cells (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>C). To mitigate the
ambiguity between uptake and MRI signal enhancement of scrambled peptide-NEMO
particles, cell labeling of T47D and MCF10A cells with both EPPT-
and scrambled peptide-conjugated blank particles with no MnO inside
was carried out at 30, 45, and 60 min. The data demonstrated &#x0223c;33%
MRI signal enhancement for scrambled peptide-conjugated blank particles
compared to no signal enhancement when cells were labeled with EPPT-conjugated
blank particles. This raises the baseline signal for scrambled-peptide
groups. In other words, scrambled peptide particles without metal
were able to enhance the MRI signal, which partially explains why
a higher MRI signal is observed for scrambled peptide-NEMO particles
despite low cell uptake by ICP-MS. We also evaluated the zeta potential
of NEMO particles and blank particles with attached EPPT peptides
versus scrambled peptides to rule out any differential impact of electrostatic
surface charge. Peptide type did not significantly change zeta potential
as shown by the obtained values of &#x02212;18.4 &#x000b1; 0.6 mV for
EPPT-NEMO versus &#x02212;16 &#x000b1; 0.7 mV for scrambled peptide-NEMO
and &#x02212;26.6 &#x000b1; 0.6 mV for EPPT-blank nanoparticles versus
&#x02212;31 &#x000b1; 0.4 mV for scrambled peptide-blank nanoparticles.
This new discovery regarding scrambled-peptide-induced <italic>T</italic><sub>1</sub>-weighted MRI enhancement warrants further investigation.</p><p>Additionally, the MRI scans of the media were acquired at all time
points to analyze the percent signal change of exocytosed Mn<sup>2+</sup> ions when compared to unlabeled cells (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00365/suppl_file/mt5c00365_si_001.pdf">Figure S2</ext-link>). It is important to observe that MRI signal alterations
remained below 100% across all experimental groups. The percentage
change in longitudinal relaxation rate (%&#x00394;<italic>R</italic><sub>1</sub>) in the media surrounding T47D cells treated with EPPT-NEMO
showed an upward trend from 15 to 45 min. When T47D and MCF10A cells
labeled with EPPT-NEMO were compared, no notable disparities in %&#x00394;<italic>R</italic><sub>1</sub> were detected in their respective media between
15 and 45 min. Surprisingly, T47D cells treated with the scrambled
peptide-NEMO exhibited significantly higher %&#x00394;<italic>R</italic><sub>1</sub> values at both 15 and 30 min, in contrast to their counterparts
incubated with EPPT-NEMO.</p><p>The MRI signal of NEMO particles is
elicited when they are endocytosed
into the cells inside early endosomes (pH = 6.5), late endosomes 
(pH = 5.5), and lysosomes (pH = 4.5), having a range of low pH<sup><xref ref-type="bibr" rid="ref47">47</xref>,<xref ref-type="bibr" rid="ref48">48</xref></sup> to dissociate MnO into Mn<sup>2+</sup> and O<sup>2&#x02013;</sup>. The endocytic pathway consists of vesicles known as endosomes,
which progress linearly from an early endosome to a late endosome
before ultimately fusing with cellular compartments, lysosomes. Lysosomes
are repositories of specialized catalytic proteins that facilitate
degradation by having the most acidic pH. Any material engulfed by
the cell through this internalization pathway is first sequestered
within endosomes and, subsequently, delivered to lysosomes, where
it undergoes active disintegration by enzymatic processes.</p><p>To
understand how intracellular trafficking of NEMO particles within
the vesicles affects the MRI signal, we performed cell uptake studies
and labeling with conjugated NEMO particles to assess the localization
of particles within early and late endosomes versus those within lysosomes.
T47D and MCF10A cells were exposed to either EPPT-NEMO or scrambled
peptide-NEMO particles over 45 min at a concentration of [Mn] = 6.5
&#x003bc;g/mL, similar to that in MRI studies. After incubating NEMO
particles with cells at desired time points, cells were fixed and
imaged under a confocal microscope to determine colocalization of
Cy5 NEMO particles (pseudocolored yellow) with early endosomes (RFP),
late endosomes (GFP), and lysosomes (GFP) as shown in <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>. We hypothesized that the
MRI signal would be greater when the NEMO particles were localized
in late endosomes and/or lysosomes due to their pH being more acidic
compared to early endosomes. This hypothesis is based on enhanced
dissociation of MnO to Mn<sup>2+</sup> at a lower pH.</p><fig id="fig5" position="float"><label>Figure 5</label><caption><p>Representative confocal
microscopy images of NEMO particles (pseudocolored
yellow) colocalized with early endosomes (red, A&#x02013;C), late endosomes
(green, D&#x02013;F) and lysosomes (green, G&#x02013;I) of MCF10A and
T47D cells at 30 min. Representative cells (dotted circles) are shown
at a higher magnification in the boxed insets. EPPT-NEMO particles
are seen to colocalize with early and late endosomes after 30 min.
Scale bars: 100 &#x003bc;m.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mt5c00365_0005" id="gr5" position="float"/></fig><p>Since the peak of the MRI signal was observed starting at 30 min
in breast cancer cells, we were interested in determining the percentage
of NEMO particles colocalized with endosomes and lysosomes at time
points until 45 min to determine particle uptake (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>). We observed the highest
colocalization of EPPT-NEMO with early endosomes, late endosomes,
and lysosomes of T47D compared to scrambled peptide-NEMO with T47D
and MCF10A with EPPT-NEMO after 15 min. This could indicate that at
15 min, the EPPT-NEMO gets taken up by T47D but does not degrade enough
to have a strong MRI signal enhancement (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>B). Interestingly, we observed overall low
colocalization of EPPT-NEMO at 30 and 45 min with all three early
endosomes, late endosomes, and lysosomes in T47D cells. This can be
attributed to significant digestion of the particles in the low pH
endosomes/lysosomes from 15 to 45 min, which would dissociate the
polymers and release the encapsulated Cy5 dye to diminish its detectability
on confocal microscopy. In summary, confocal microscopy confirmed
EPPT-NEMO particles are taken up by the endosomal/lysosomal pathway
in cancer cells to facilitate their degradation and activation of
the MRI signal.</p><fig id="fig6" position="float"><label>Figure 6</label><caption><p>Quantification of the colocalized area of NEMO particles
with endosomes
and lysosomes in benign versus malignant mammary cells over 45 min.
Percent colocalization of EPPT-NEMO particles and scrambled peptide-NEMO
particles with (A) early endosomes (B) late endosomes and (C) lysosomes
in MCF10A and T47D cells over time. Error bars are standard deviation.
* <italic>p</italic> &#x02264; 0.05, ** <italic>p</italic> &#x02264;
0.01, *** <italic>p</italic> &#x02264; 0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mt5c00365_0006" id="gr6" position="float"/></fig><p>MnO nanoparticles have demonstrated significant potential as <italic>T</italic><sub>1</sub> MRI contrast agents, with their efficacy varying
across studies depending on nanoparticle design, surface modification,
and cellular targeting. Comparing the reported <italic>T</italic><sub>1</sub> relaxation times and <italic>R</italic><sub>1</sub> values
from previous studies with our data set reveals significant differences
in performance. For instance, at our low labeling dose of [Mn] = 6.5
&#x003bc;g/mL or 0.12 mM Mn, we achieved a signal enhancement of 276%
within a clinically relevant time of 30 min in the malignant cells
incubated with EPPT-NEMO. Notably, other studies have shown lower
MRI signal enhancement in malignant cells labeled with higher Mn doses
over longer incubation times. For example, Li et al. achieved a signal
enhancement of &#x0223c;114% in renal carcinoma cells after 24 h using
a dose of 0.2 mM Mn delivered by an AS114 aptamer-targeted MnO-PEG
nanoprobe.<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> Although their MnO-PEG nanoparticles
displayed higher <italic>r</italic><sub>1</sub> than our EPPT-NEMO
particles outside of cells (12.9 mM<sup>&#x02013;1</sup> s<sup>&#x02013;1</sup> for their intact particles versus 6.6 mM<sup>&#x02013;1</sup> s<sup>&#x02013;1</sup> for our fully digested particles), this high baseline
signal of their intact particles would limit pH responsiveness and
required 24 h for the control untargeted probe to clear out of mouse
tumors in vivo for <italic>T</italic><sub>1</sub>-weighted MRI signal
to return to precontrast levels.<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> Due
to their specific intracellular activation in malignant cells, we
hypothesize that NEMO particles should also demonstrate faster in
vivo benign versus malignant tumor discrimination without the need
for clearance of unendocytosed intratumoral probes. Furthermore, Hu
et al. demonstrated a signal enhancement in lung carcinoma cells at
a dose of [Mn] = 100 &#x003bc;g /mL after incubating for 6 h<sup><xref ref-type="bibr" rid="ref50">50</xref></sup>; however, the MRI scans were not quantified
for % signal enhancement. In addition, the lack of active targeting
on their MnO nanoparticles may limit the differentiation of benign
from malignant tumor cells. Though it is difficult to directly compare
the results due to multiple factors such as the different nanoparticle
designs, cell types, cell receptor targets, and MRI magnetic field
strengths used, our EPPT-NEMO particles show promise as an alternative
MRI contrast agent with quick, robust, and specific <italic>T</italic><sub>1</sub>-weighted signal activation.</p><p>There are several
limitations associated with our study that can
be addressed with future work: (1) Confocal microscopy tracks the
Cy5 encapsulated dye inside NEMO particles and not Mn directly. In
future studies, X-ray fluorescence microscopy could help to track
the elemental Mn<sup>2+</sup> ions in biological samples over time
at cellular levels.<sup><xref ref-type="bibr" rid="ref51">51</xref>,<xref ref-type="bibr" rid="ref52">52</xref></sup> (2) As only luminal A T47D breast
cancer cells were tested here, evaluating NEMO particle labeling with
other breast cancer subtypes including luminal B, HER2, and triple
negative would be useful to determine the generalizability of uMUC-1
targeting. (3) As an alternative to the discrete time points for labeling
used in this study, live cell imaging could provide further insights
into the dynamics of NEMO particle uptake, localization, and dissolution
in low pH endosomes and lysosomes. (4) Although endocytosis pathways
were not considered herein, additional studies could be performed
with different pathway inhibitors during cell labeling to determine
NEMO&#x02019;s uptake mechanism. (5) The in vitro specific <italic>T</italic><sub>1</sub> MRI signal enhancement observed provides feasibility
for applying NEMO particles for enhanced breast cancer detection.
However, in vivo investigation is necessary in preclinical models
for future work, which will determine EPPT-NEMO biodistribution, toxicity,
and MRI signal activation in breast cancer mouse models versus clinically
used Gd-chelates. In order for NEMO particles to be safely used in
future clinical applications, a dose response will be performed to
determine the lowest effective dose for a specific elevated <italic>T</italic><sub>1</sub> MRI signal.</p></sec><sec id="sec4"><title>Conclusions</title><p>Novel
uMUC-1 targeted NEMO particles were synthesized, characterized,
and evaluated for cell uptake and MRI properties in benign versus
malignant mammary cells. The uMUC-1 targeting peptide EPPT was successfully
attached and on par with other previously reported particles. In vitro
studies confirmed increased specificity of EPPT-NEMO with malignant
mammary cells when compared to benign mammary cells, with robust <italic>T</italic><sub>1</sub>-weighted MRI signal generation in breast cancer
cells at a clinically relevant time frame of 30 min. Despite the 276%
signal enhancement on MRI at 30 min, EPPT-NEMO did not have significant
colocalization with the low pH late endosomes and lysosomes in breast
cancer cells, which suggested rapid particle degradation, release
of encapsulated Cy5, and dilution of its signal on confocal microscopy.
Our results demonstrate the feasibility of EPPT-NEMO particles in
differentiating malignant from benign mammary cells on <italic>T</italic><sub>1</sub>-weighted MRI and provide rationale for future in vivo
preclinical testing to establish biodistribution, toxicity, and MRI
signal activation in mammary tumors.</p></sec></body><back><notes id="notes1" notes-type="si"><title>Supporting Information Available</title><p>The
Supporting Information is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acsabm.5c00365?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsabm.5c00365</ext-link>.<list id="silist" list-type="simple"><list-item><p>Surface chemistry, morphology,
stability, and peptide
attachment of EPPT-NEMO particles; absolute and relative MRI quantification
results of T47D cells incubated with or without contrast agents over
1 h; absolute and relative MRI quantification results of MCF10A cells
incubated with or without contrast agents over 1 h; quantification
of the MRI signal change of media supernatant collected after exposing
cells to NEMO particles over 60 min (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00365/suppl_file/mt5c00365_si_001.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mt5c00365_si_001.pdf"><caption><p>mt5c00365_si_001.pdf</p></caption></media></supplementary-material></sec><notes notes-type="" id="notes4"><title>Author Present Address</title><p><sup>#</sup> Department
of Radiology, Sloan Kettering Institute, Memorial Sloan
Kettering Cancer Center, New York, New York, United States</p></notes><notes notes-type="" id="notes5"><title>Author Present Address</title><p><sup>&#x02207;</sup> Molecular Pharmacology Program, Sloan Kettering Institute, Memorial
Sloan Kettering Cancer Center, New York, New York, United States</p></notes><notes notes-type="" id="notes2"><title>Author Contributions</title><p>The manuscript
was written through the contributions of all authors. All authors
have given approval to the final version of the manuscript. Conceptualization&#x02013;D.M.P.,
A.R.G., C.M.d.l.T., B.M.S., H.T.S., B.D., M.F.B.; Methodology&#x02013;D.M.P.,
A.R.G., C.M.d.l.T., B.M.S., A.J.S., B.D., M.F.B.; Validation&#x02013;D.M.P.,
A.R.G., C.M.d.l.T., B.M.S., A.J.S.; Formal analysis&#x02013;D.M.P.,
A.R.G., C.M.d.l.T., B.M.S., A.J.S., H.T.S.; Investigation&#x02013;D.M.P.,
A.R.G., C.M.d.l.T., B.M.S., A.J.S; Writing&#x02013;Original Draft&#x02013;D.M.P.,
A.R.G., C.M.d.l.T., B.M.S., M.F.B.; Writing&#x02013;Review and Editing&#x02013;D.M.P.,
A.R.G., C.M.d.l.T., B.M.S., A.J.S., H.T.S., B.D., M.F.B.; Visualization&#x02013;D.M.P.,
A.R.G., C.M.d.l.T., B.M.S., A.J.S., B.D., M.F.B.; Supervision&#x02013;M.F.B.;
Project Administration&#x02013;D.M.P., A.R.G., C.M.d.l.T., M.F.B.;
Funding Acquisition&#x02013;C.M.d.l.T., M.F.B.</p></notes><notes notes-type="funding-statement" id="notes3"><p>This work was
supported by the National Institutes of Health [P20 GM121322; 1R15CA274189&#x02013;01A1]
and West Virginia University&#x02019;s Health Sciences Center International
Fellowship. Equipment utilized in WVU&#x02019;s Flow Cytometry and
Imaging Facilities was supported by the National Institutes of Health
[S10OD016165, U51GM104942, P20GM109098, P30GM121322, P20GM103434,
P20GM10343, P30GM103488, P20GM121322, U54GM104942]. The sponsors had
no role in the study design, collection, analysis, and interpretation
of data, in writing the report, or in the decision to submit the article
for publication.</p></notes><notes notes-type="COI-statement" id="notes6"><p>The
authors
declare no competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>The authors would like to thank Dr. Qiang Wang for
advice on interpretation and analysis of XPS data for uMUC-1 peptide
conjugation to NEMO particles, Robert Vincent for measuring Mn content
of NEMO particles and labeled cells with ICP techniques, Dr. Kathy
Brundage for assistance interpreting and analyzing flow cytometry
data and for running the Nanosight analysis and zeta potential of
NEMO particles, Dr. Paolo Fagone for providing access to the Zetasizer
Nano ZS (Malvern Instruments) for DLS experiments, Dr. Bradley Webb
and Dr. Elena Pugacheva for their advice on the biological interpretation
of the confocal data, Krystal A. Hughes for helping with processing
confocal images on FIJI/ImageJ, the WVU Shared Research Facility for
use of their equipment including the SEM, XPS, and FTIR and the In
Vivo Multifunctional Magnetic Resonance center for the use of their
1 T MRI machine.</p></ack><glossary id="dl1"><def-list><title>Abbreviations</title><def-item><term>DLS</term><def><p>dynamic light scattering</p></def></def-item><def-item><term>EPPT</term><def><p>uMUC-1 targeting peptide</p></def></def-item><def-item><term>EPPT-NEMO</term><def><p>uMUC-1 targeting
peptide conjugated
NEMO particles</p></def></def-item><def-item><term>ER</term><def><p>estrogen receptor</p></def></def-item><def-item><term>FBS</term><def><p>fetal bovine serum</p></def></def-item><def-item><term>FTIR</term><def><p>Fourier transform infrared spectroscopy</p></def></def-item><def-item><term>Gd</term><def><p>gadolinium</p></def></def-item><def-item><term>MnO</term><def><p>manganese oxide</p></def></def-item><def-item><term>HCl</term><def><p>hydrochloric acid</p></def></def-item><def-item><term>HER2</term><def><p>human epidermal growth factor receptor
2</p></def></def-item><def-item><term>ICP-MS</term><def><p>inductively
coupled plasma&#x02013;mass
spectrometry</p></def></def-item><def-item><term>ICP-OES</term><def><p>inductively coupled plasma&#x02013;optical
emission spectrometry</p></def></def-item><def-item><term>MEGM</term><def><p>mammary epithelial cell growth
medium</p></def></def-item><def-item><term>Mn(II)(acac)<sub>2</sub></term><def><p>manganese(II)
acetylacetonate</p></def></def-item><def-item><term>MRI</term><def><p>magnetic resonance imaging</p></def></def-item><def-item><term>MUC-1</term><def><p>Mucin-1</p></def></def-item><def-item><term>NEMO</term><def><p>nano-encapsulated manganese oxide</p></def></def-item><def-item><term>PBS</term><def><p>phosphate buffered saline</p></def></def-item><def-item><term>PLGA</term><def><p>poly(D,<sc>l</sc>-lactide-<italic>co</italic>-glycolide)</p></def></def-item><def-item><term>PR</term><def><p>progesterone receptor</p></def></def-item><def-item><term>PVA</term><def><p>poly(vinyl alcohol)</p></def></def-item><def-item><term>SEM</term><def><p>scanning electron microscopy</p></def></def-item><def-item><term>TBTA</term><def><p>tris((1-benzyl)-4-triazolyl)methyl)
amine</p></def></def-item><def-item><term>uMUC-1</term><def><p>underglycosylated
mucin-1</p></def></def-item><def-item><term>XPS</term><def><p>X-ray
photoelectron spectroscopy</p></def></def-item><def-item><term>&#x003b6;-potential</term><def><p>zeta potential</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Bray</surname><given-names>F.</given-names></name>; <name><surname>Laversanne</surname><given-names>M.</given-names></name>; <name><surname>Sung</surname><given-names>H.</given-names></name>; <name><surname>Ferlay</surname><given-names>J.</given-names></name>; <name><surname>Siegel</surname><given-names>R. L.</given-names></name>; <name><surname>Soerjomataram</surname><given-names>I.</given-names></name>; <name><surname>Jemal</surname><given-names>A.</given-names></name>
<article-title>Global Cancer Statistics 2022: GLOBOCAN
Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185
Countries</article-title>. <source>CA: A Cancer Journal for Clinicians</source>
<year>2024</year>, <volume>74</volume> (<issue>3</issue>), <fpage>229</fpage>&#x02013;<lpage>263</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21834</pub-id>.<pub-id pub-id-type="pmid">38572751</pub-id>
</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="undeclared" id="cit2"><collab>American Cancer Society</collab>. <source>Breast
Cancer Facts &#x00026; Figures 2022&#x02013;2024</source>; <publisher-name>American Cancer Society, Inc.</publisher-name>: <publisher-loc>Atlanta</publisher-loc>, <year>2022</year>, <fpage>48</fpage>.</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="weblink" id="cit3"><source>Limitations of
Mammograms | How Often are Mammograms Wrong?</source><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/mammograms/limitations-of-mammograms.html">https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/mammograms/limitations-of-mammograms.html</uri> (accessed 2020&#x02013;09&#x02013;12).</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Durand</surname><given-names>M. A.</given-names></name>; <name><surname>Friedewald</surname><given-names>S. M.</given-names></name>; <name><surname>Plecha</surname><given-names>D. M.</given-names></name>; <name><surname>Copit</surname><given-names>D. S.</given-names></name>; <name><surname>Barke</surname><given-names>L. D.</given-names></name>; <name><surname>Rose</surname><given-names>S. L.</given-names></name>; <name><surname>Hayes</surname><given-names>M. K.</given-names></name>; <name><surname>Greer</surname><given-names>L. N.</given-names></name>; <name><surname>Dabbous</surname><given-names>F. M.</given-names></name>; <name><surname>Conant</surname><given-names>E. F.</given-names></name>
<article-title>False-Negative Rates of Breast Cancer Screening with
and without Digital Breast Tomosynthesis</article-title>. <source>Radiology</source>
<year>2021</year>, <volume>298</volume> (<issue>2</issue>), <fpage>296</fpage>&#x02013;<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1148/radiol.2020202858</pub-id>.<pub-id pub-id-type="pmid">33258744</pub-id>
</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Tosteson</surname><given-names>A. N. A.</given-names></name>; <name><surname>Fryback</surname><given-names>D. G.</given-names></name>; <name><surname>Hammond</surname><given-names>C. S.</given-names></name>; <name><surname>Hanna</surname><given-names>L. G.</given-names></name>; <name><surname>Grove</surname><given-names>M. R.</given-names></name>; <name><surname>Brown</surname><given-names>M.</given-names></name>; <name><surname>Wang</surname><given-names>Q.</given-names></name>; <name><surname>Lindfors</surname><given-names>K.</given-names></name>; <name><surname>Pisano</surname><given-names>E. D.</given-names></name>
<article-title>Consequences
of False-Positive Screening Mammograms</article-title>. <source>JAMA
Intern Med.</source>
<year>2014</year>, <volume>174</volume> (<issue>6</issue>), <fpage>954</fpage>&#x02013;<lpage>961</lpage>. <pub-id pub-id-type="doi">10.1001/jamainternmed.2014.981</pub-id>.<pub-id pub-id-type="pmid">24756610</pub-id>
</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Song</surname><given-names>D.</given-names></name>; <name><surname>Kang</surname><given-names>B. J.</given-names></name>; <name><surname>Kim</surname><given-names>S. H.</given-names></name>; <name><surname>Lee</surname><given-names>J.</given-names></name>; <name><surname>Park</surname><given-names>G. E.</given-names></name>
<article-title>The Frequency
and Causes of Not-Detected Breast Malignancy in Dynamic Contrast-Enhanced
MRI</article-title>. <source>Diagnostics</source>
<year>2022</year>, <volume>12</volume> (<issue>11</issue>), <fpage>2575</fpage><pub-id pub-id-type="doi">10.3390/diagnostics12112575</pub-id>.<pub-id pub-id-type="pmid">36359419</pub-id>
</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Kuhl</surname><given-names>C. K.</given-names></name>; <name><surname>Keulers</surname><given-names>A.</given-names></name>; <name><surname>Strobel</surname><given-names>K.</given-names></name>; <name><surname>Schneider</surname><given-names>H.</given-names></name>; <name><surname>Gaisa</surname><given-names>N.</given-names></name>; <name><surname>Schrading</surname><given-names>S.</given-names></name>
<article-title>Not All False
Positive Diagnoses
Are Equal: On the Prognostic Implications of False-Positive Diagnoses
Made in Breast MRI versus in Mammography/Digital Tomosynthesis Screening</article-title>. <source>Breast Cancer Res.</source>
<year>2018</year>, <volume>20</volume> (<issue>1</issue>), <fpage>13</fpage><pub-id pub-id-type="doi">10.1186/s13058-018-0937-7</pub-id>.<pub-id pub-id-type="pmid">29426360</pub-id>
</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Gao</surname><given-names>Z.</given-names></name>; <name><surname>Ma</surname><given-names>T.</given-names></name>; <name><surname>Zhao</surname><given-names>E.</given-names></name>; <name><surname>Docter</surname><given-names>D.</given-names></name>; <name><surname>Yang</surname><given-names>W.</given-names></name>; <name><surname>Stauber</surname><given-names>R. H.</given-names></name>; <name><surname>Gao</surname><given-names>M.</given-names></name>
<article-title>Small Is Smarter: Nano MRI Contrast
Agents&#x02013;Advantages and
Recent Achievements</article-title>. <source>Small</source>
<year>2016</year>, <volume>12</volume> (<issue>5</issue>), <fpage>556</fpage>&#x02013;<lpage>576</lpage>. <pub-id pub-id-type="doi">10.1002/smll.201502309</pub-id>.<pub-id pub-id-type="pmid">26680328</pub-id>
</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Martinez
de la Torre</surname><given-names>C.</given-names></name>; <name><surname>Grossman</surname><given-names>J. H.</given-names></name>; <name><surname>Bobko</surname><given-names>A. A.</given-names></name>; <name><surname>Bennewitz</surname><given-names>M. F.</given-names></name>
<article-title>Tuning
the Size and Composition of Manganese Oxide Nanoparticles through
Varying Temperature Ramp and Aging Time</article-title>. <source>PLoS
One</source>
<year>2020</year>, <volume>15</volume> (<issue>9</issue>), <elocation-id>e0239034</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0239034</pub-id>.<pub-id pub-id-type="pmid">32946514</pub-id>
</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Bennewitz</surname><given-names>M. F.</given-names></name>; <name><surname>Lobo</surname><given-names>T. L.</given-names></name>; <name><surname>Nkansah</surname><given-names>M. K.</given-names></name>; <name><surname>Ulas</surname><given-names>G.</given-names></name>; <name><surname>Brudvig</surname><given-names>G. W.</given-names></name>; <name><surname>Shapiro</surname><given-names>E. M.</given-names></name>
<article-title>Biocompatible and pH-Sensitive PLGA
Encapsulated MnO
Nanocrystals for Molecular and Cellular MRI</article-title>. <source>ACS Nano</source>
<year>2011</year>, <volume>5</volume> (<issue>5</issue>), <fpage>3438</fpage>&#x02013;<lpage>3446</lpage>. <pub-id pub-id-type="doi">10.1021/nn1019779</pub-id>.<pub-id pub-id-type="pmid">21495676</pub-id>
</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Cai</surname><given-names>X.</given-names></name>; <name><surname>Zhu</surname><given-names>Q.</given-names></name>; <name><surname>Zeng</surname><given-names>Y.</given-names></name>; <name><surname>Zeng</surname><given-names>Q.</given-names></name>; <name><surname>Chen</surname><given-names>X.</given-names></name>; <name><surname>Zhan</surname><given-names>Y.</given-names></name>
<article-title>Manganese
Oxide Nanoparticles As MRI Contrast Agents In Tumor Multimodal Imaging
And Therapy</article-title>. <source>Int. J. Nanomedicine</source>
<year>2019</year>, <volume>14</volume>, <fpage>8321</fpage>&#x02013;<lpage>8344</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S218085</pub-id>.<pub-id pub-id-type="pmid">31695370</pub-id>
</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Chen</surname><given-names>Y.</given-names></name>; <name><surname>Yin</surname><given-names>Q.</given-names></name>; <name><surname>Ji</surname><given-names>X.</given-names></name>; <name><surname>Zhang</surname><given-names>S.</given-names></name>; <name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>Zheng</surname><given-names>Y.</given-names></name>; <name><surname>Sun</surname><given-names>Y.</given-names></name>; <name><surname>Qu</surname><given-names>H.</given-names></name>; <name><surname>Wang</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Zhang</surname><given-names>K.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Shi</surname><given-names>J.</given-names></name>
<article-title>Manganese Oxide-Based
Multifunctionalized Mesoporous Silica Nanoparticles for pH-Responsive
MRI, Ultrasonography and Circumvention of MDR in Cancer Cells</article-title>. <source>Biomaterials</source>
<year>2012</year>, <volume>33</volume> (<issue>29</issue>), <fpage>7126</fpage>&#x02013;<lpage>7137</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.06.059</pub-id>.<pub-id pub-id-type="pmid">22789722</pub-id>
</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Park</surname><given-names>M.</given-names></name>; <name><surname>Lee</surname><given-names>N.</given-names></name>; <name><surname>Choi</surname><given-names>S. H.</given-names></name>; <name><surname>An</surname><given-names>K.</given-names></name>; <name><surname>Yu</surname><given-names>S.-H.</given-names></name>; <name><surname>Kim</surname><given-names>J. H.</given-names></name>; <name><surname>Kwon</surname><given-names>S.-H.</given-names></name>; <name><surname>Kim</surname><given-names>D.</given-names></name>; <name><surname>Kim</surname><given-names>H.</given-names></name>; <name><surname>Baek</surname><given-names>S.-I.</given-names></name>; <name><surname>Ahn</surname><given-names>T.-Y.</given-names></name>; <name><surname>Park</surname><given-names>O. K.</given-names></name>; <name><surname>Son</surname><given-names>J. S.</given-names></name>; <name><surname>Sung</surname><given-names>Y.-E.</given-names></name>; <name><surname>Kim</surname><given-names>Y.-W.</given-names></name>; <name><surname>Wang</surname><given-names>Z.</given-names></name>; <name><surname>Pinna</surname><given-names>N.</given-names></name>; <name><surname>Hyeon</surname><given-names>T.</given-names></name>
<article-title>Large-Scale
Synthesis of Ultrathin Manganese Oxide Nanoplates and Their Applications
to T1MRI Contrast Agents</article-title>. <source>Chem. Mater.</source>
<year>2011</year>, <volume>23</volume> (<issue>14</issue>), <fpage>3318</fpage>&#x02013;<lpage>3324</lpage>. <pub-id pub-id-type="doi">10.1021/cm200414c</pub-id>.</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Duan</surname><given-names>B.</given-names></name>; <name><surname>Wang</surname><given-names>D.</given-names></name>; <name><surname>Wu</surname><given-names>H.</given-names></name>; <name><surname>Xu</surname><given-names>P.</given-names></name>; <name><surname>Jiang</surname><given-names>P.</given-names></name>; <name><surname>Xia</surname><given-names>G.</given-names></name>; <name><surname>Liu</surname><given-names>Z.</given-names></name>; <name><surname>Wang</surname><given-names>H.</given-names></name>; <name><surname>Guo</surname><given-names>Z.</given-names></name>; <name><surname>Chen</surname><given-names>Q.</given-names></name>
<article-title>Core&#x02013;Shell
Structurized Fe3O4@C@MnO2 Nanoparticles as pH Responsive T1-T2* Dual-Modal
Contrast Agents for Tumor Diagnosis</article-title>. <source>ACS Biomater.
Sci. Eng.</source>
<year>2018</year>, <volume>4</volume> (<issue>8</issue>), <fpage>3047</fpage>&#x02013;<lpage>3054</lpage>. <pub-id pub-id-type="doi">10.1021/acsbiomaterials.8b00287</pub-id>.<pub-id pub-id-type="pmid">33435024</pub-id>
</mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Hao</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name>; <name><surname>Zhao</surname><given-names>H.</given-names></name>; <name><surname>Niu</surname><given-names>M.</given-names></name>; <name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>Zheng</surname><given-names>C.</given-names></name>; <name><surname>Zhang</surname><given-names>H.</given-names></name>; <name><surname>Chang</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>
<article-title>Multifunctional
Nanosheets Based on Folic Acid Modified Manganese
Oxide for Tumor-Targeting Theranostic Application</article-title>. <source>Nanotechnology</source>
<year>2016</year>, <volume>27</volume> (<issue>2</issue>), <elocation-id>025101</elocation-id><pub-id pub-id-type="doi">10.1088/0957-4484/27/2/025101</pub-id>.<pub-id pub-id-type="pmid">26629735</pub-id>
</mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Shi</surname><given-names>Y.</given-names></name>; <name><surname>Guenneau</surname><given-names>F.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>H&#x000e9;lary</surname><given-names>C.</given-names></name>; <name><surname>Coradin</surname><given-names>T.</given-names></name>
<article-title>MnO2-Gated Nanoplatforms with Targeted
Controlled Drug
Release and Contrast-Enhanced MRI Properties: From 2D Cell Culture
to 3D Biomimetic Hydrogels</article-title>. <source>Nanotheranostics</source>
<year>2018</year>, <volume>2</volume> (<issue>4</issue>), <fpage>403</fpage>&#x02013;<lpage>416</lpage>. <pub-id pub-id-type="doi">10.7150/ntno.28046</pub-id>.<pub-id pub-id-type="pmid">30324085</pub-id>
</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Dai</surname><given-names>X.</given-names></name>; <name><surname>Xiang</surname><given-names>L.</given-names></name>; <name><surname>Li</surname><given-names>T.</given-names></name>; <name><surname>Bai</surname><given-names>Z.</given-names></name>
<article-title>Cancer Hallmarks, Biomarkers
and Breast Cancer Molecular Subtypes</article-title>. <source>J. Cancer</source>
<year>2016</year>, <volume>7</volume> (<issue>10</issue>), <fpage>1281</fpage>&#x02013;<lpage>1294</lpage>. <pub-id pub-id-type="doi">10.7150/jca.13141</pub-id>.<pub-id pub-id-type="pmid">27390604</pub-id>
</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Dall</surname><given-names>G.</given-names></name>; <name><surname>Vieusseux</surname><given-names>J.</given-names></name>; <name><surname>Unsworth</surname><given-names>A.</given-names></name>; <name><surname>Anderson</surname><given-names>R.</given-names></name>; <name><surname>Britt</surname><given-names>K.</given-names></name>
<article-title>Low Dose,
Low Cost Estradiol Pellets Can Support MCF-7 Tumour Growth in Nude
Mice without Bladder Symptoms</article-title>. <source>J. Cancer</source>
<year>2015</year>, <volume>6</volume> (<issue>12</issue>), <fpage>1331</fpage>&#x02013;<lpage>1336</lpage>. <pub-id pub-id-type="doi">10.7150/jca.10890</pub-id>.<pub-id pub-id-type="pmid">26640593</pub-id>
</mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Mullen</surname><given-names>P.</given-names></name>; <name><surname>Ritchie</surname><given-names>A.</given-names></name>; <name><surname>Langdon</surname><given-names>S. P.</given-names></name>; <name><surname>Miller</surname><given-names>W. R.</given-names></name>
<article-title>Effect of Matrigel
on the Tumorigenicity of Human Breast and Ovarian Carcinoma Cell Lines</article-title>. <source>Intl Journal of Cancer</source>
<year>1996</year>, <volume>67</volume> (<issue>6</issue>), <fpage>816</fpage>&#x02013;<lpage>820</lpage>. <pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19960917)67:6&#x0003c;816::AID-IJC10&#x0003e;3.0.CO;2-#</pub-id>.</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Weigel</surname><given-names>M. T.</given-names></name>; <name><surname>Dowsett</surname><given-names>M.</given-names></name>
<article-title>Current and Emerging
Biomarkers in Breast Cancer: Prognosis
and Prediction</article-title>. <source>Endocrine-Related Cancer</source>
<year>2010</year>, <volume>17</volume> (<issue>4</issue>), <fpage>R245</fpage>&#x02013;<lpage>R262</lpage>. <pub-id pub-id-type="doi">10.1677/ERC-10-0136</pub-id>.<pub-id pub-id-type="pmid">20647302</pub-id>
</mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="undeclared" id="cit21"><person-group person-group-type="allauthors"><name><surname>Ellis</surname><given-names>I. O.</given-names></name></person-group><source>Chapter 16 - Tumors
of the Breast</source>. <fpage>92</fpage>.</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Cheng</surname><given-names>Z.</given-names></name>; <name><surname>Zaki</surname><given-names>A. A.</given-names></name>; <name><surname>Hui</surname><given-names>J. Z.</given-names></name>; <name><surname>Muzykantov</surname><given-names>V. R.</given-names></name>; <name><surname>Tsourkas</surname><given-names>A.</given-names></name>
<article-title>Multifunctional Nanoparticles: Cost versus Benefit
of Adding Targeting and Imaging Capabilities</article-title>. <source>Science</source>
<year>2012</year>, <volume>338</volume> (<issue>6109</issue>), <fpage>903</fpage>&#x02013;<lpage>910</lpage>. <pub-id pub-id-type="doi">10.1126/science.1226338</pub-id>.<pub-id pub-id-type="pmid">23161990</pub-id>
</mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Park</surname><given-names>K.</given-names></name>; <name><surname>Han</surname><given-names>S.</given-names></name>; <name><surname>Shin</surname><given-names>E.</given-names></name>; <name><surname>Kim</surname><given-names>H. J.</given-names></name>; <name><surname>Kim</surname><given-names>J. Y.</given-names></name>
<article-title>EGFR Gene and Protein
Expression in Breast Cancers</article-title>. <source>European Journal
of Surgical Oncology</source>
<year>2007</year>, <volume>33</volume> (<issue>8</issue>), <fpage>956</fpage>&#x02013;<lpage>960</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejso.2007.01.033</pub-id>.<pub-id pub-id-type="pmid">17374474</pub-id>
</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Moore</surname><given-names>A.</given-names></name>; <name><surname>Medarova</surname><given-names>Z.</given-names></name>; <name><surname>Potthast</surname><given-names>A.</given-names></name>; <name><surname>Dai</surname><given-names>G.</given-names></name>
<article-title>In Vivo Targeting
of
Underglycosylated MUC-1 Tumor Antigen Using a Multimodal Imaging Probe</article-title>. <source>Cancer Res.</source>
<year>2004</year>, <volume>64</volume> (<issue>5</issue>), <fpage>1821</fpage>&#x02013;<lpage>1827</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-3230</pub-id>.<pub-id pub-id-type="pmid">14996745</pub-id>
</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Apostolopoulos</surname><given-names>V.</given-names></name>; <name><surname>Stojanovska</surname><given-names>L.</given-names></name>; <name><surname>Gargosky</surname><given-names>S. E.</given-names></name>
<article-title>MUC1 (CD227): A Multi-Tasked Molecule</article-title>. <source>Cell. Mol. Life Sci.</source>
<year>2015</year>, <volume>72</volume> (<issue>23</issue>), <fpage>4475</fpage>&#x02013;<lpage>4500</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-015-2014-z</pub-id>.<pub-id pub-id-type="pmid">26294353</pub-id>
</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Movahedin</surname><given-names>M.</given-names></name>; <name><surname>Brooks</surname><given-names>T. M.</given-names></name>; <name><surname>Supekar</surname><given-names>N. T.</given-names></name>; <name><surname>Gokanapudi</surname><given-names>N.</given-names></name>; <name><surname>Boons</surname><given-names>G.-J.</given-names></name>; <name><surname>Brooks</surname><given-names>C. L.</given-names></name>
<article-title>Glycosylation of
MUC1 Influences
the Binding of a Therapeutic Antibody by Altering the Conformational
Equilibrium of the Antigen</article-title>. <source>Glycobiology</source>
<year>2016</year>, <volume>27</volume> (<issue>7</issue>), <fpage>677</fpage>&#x02013;<lpage>687</lpage>. <pub-id pub-id-type="doi">10.1093/glycob/cww131</pub-id>.</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Von
Mensdorff-Pouilly</surname><given-names>S.</given-names></name>; <name><surname>Moreno</surname><given-names>M.</given-names></name>; <name><surname>Verheijen</surname><given-names>R. H. M.</given-names></name>
<article-title>Natural
and Induced Humoral Responses to MUC1</article-title>. <source>Cancers</source>
<year>2011</year>, <volume>3</volume> (<issue>3</issue>), <fpage>3073</fpage>&#x02013;<lpage>3103</lpage>. <pub-id pub-id-type="doi">10.3390/cancers3033073</pub-id>.<pub-id pub-id-type="pmid">24212946</pub-id>
</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Singh</surname><given-names>R.</given-names></name>; <name><surname>Bandyopadhyay</surname><given-names>D.</given-names></name>
<article-title>MUC1: A Target Molecule for Cancer Therapy</article-title>. <source>Cancer Biology &#x00026; Therapy</source>
<year>2007</year>, <volume>6</volume> (<issue>4</issue>), <fpage>481</fpage>&#x02013;<lpage>486</lpage>. <pub-id pub-id-type="doi">10.4161/cbt.6.4.4201</pub-id>.<pub-id pub-id-type="pmid">18027437</pub-id>
</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Dr&#x000e9;au</surname><given-names>D.</given-names></name>; <name><surname>Moore</surname><given-names>L. J.</given-names></name>; <name><surname>Alvarez-Berrios</surname><given-names>M. P.</given-names></name>; <name><surname>Tarannum</surname><given-names>M.</given-names></name>; <name><surname>Mukherjee</surname><given-names>P.</given-names></name>; <name><surname>Vivero-Escoto</surname><given-names>J. L.</given-names></name>
<article-title>Mucin-1-Antibody-Conjugated
Mesoporous Silica Nanoparticles
for Selective Breast Cancer Detection in a Mucin-1 Transgenic Murine
Mouse Model</article-title>. <source>J. Biomed Nanotechnol</source>
<year>2016</year>, <volume>12</volume> (<issue>12</issue>), <fpage>2172</fpage>&#x02013;<lpage>2184</lpage>. <pub-id pub-id-type="doi">10.1166/jbn.2016.2318</pub-id>.<pub-id pub-id-type="pmid">28522938</pub-id>
</mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Okarvi</surname><given-names>S. M.</given-names></name>; <name><surname>AlJammaz</surname><given-names>I.</given-names></name>
<article-title>Development of the Tumor-Specific Antigen-Derived Synthetic
Peptides as Potential Candidates for Targeting Breast and Other Possible
Human Carcinomas</article-title>. <source>Molecules</source>
<year>2019</year>, <volume>24</volume> (<issue>17</issue>), <fpage>3142</fpage><pub-id pub-id-type="doi">10.3390/molecules24173142</pub-id>.<pub-id pub-id-type="pmid">31470531</pub-id>
</mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Khaniabadi</surname><given-names>P. M.</given-names></name>; <name><surname>Majid</surname><given-names>A. M. S. A.</given-names></name>; <name><surname>Asif</surname><given-names>M.</given-names></name>; <name><surname>Khaniabadi</surname><given-names>B. M.</given-names></name>; <name><surname>Shahbazi-Gahrouei</surname><given-names>D.</given-names></name>; <name><surname>Jaafar</surname><given-names>M. S.</given-names></name>
<article-title>Breast Cancer Cell Targeted MR Molecular
Imaging Probe: Anti-MUC1 Antibody-Based Magnetic Nanoparticles</article-title>. <source>J. Phys.: Conf. Ser.</source>
<year>2017</year>, <volume>851</volume>, <elocation-id>012014</elocation-id><pub-id pub-id-type="doi">10.1088/1742-6596/851/1/012014</pub-id>.</mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Thie</surname><given-names>H.</given-names></name>; <name><surname>Toleikis</surname><given-names>L.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>von Wasielewski</surname><given-names>R.</given-names></name>; <name><surname>Bastert</surname><given-names>G.</given-names></name>; <name><surname>Schirrmann</surname><given-names>T.</given-names></name>; <name><surname>Esteves</surname><given-names>I. T.</given-names></name>; <name><surname>Behrens</surname><given-names>C. K.</given-names></name>; <name><surname>Fournes</surname><given-names>B.</given-names></name>; <name><surname>Fournier</surname><given-names>N.</given-names></name>; <name><surname>de Romeuf</surname><given-names>C.</given-names></name>; <name><surname>Hust</surname><given-names>M.</given-names></name>; <name><surname>D&#x000fc;bel</surname><given-names>S.</given-names></name>
<article-title>Rise and Fall
of an Anti-MUC1 Specific
Antibody</article-title>. <source>PLoS One</source>
<year>2011</year>, <volume>6</volume> (<issue>1</issue>), <elocation-id>e15921</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0015921</pub-id>.<pub-id pub-id-type="pmid">21264246</pub-id>
</mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Ghosh</surname><given-names>S. K.</given-names></name>; <name><surname>Uchida</surname><given-names>M.</given-names></name>; <name><surname>Yoo</surname><given-names>B.</given-names></name>; <name><surname>Ross</surname><given-names>A. W.</given-names></name>; <name><surname>Gendler</surname><given-names>S. J.</given-names></name>; <name><surname>Gong</surname><given-names>J.</given-names></name>; <name><surname>Moore</surname><given-names>A.</given-names></name>; <name><surname>Medarova</surname><given-names>Z.</given-names></name>
<article-title>Targeted Imaging of
Breast Tumor Progression and Therapeutic Response in a Human uMUC-1
Expressing Transgenic Mouse Model</article-title>. <source>Int. J. Cancer</source>
<year>2013</year>, <volume>132</volume> (<issue>8</issue>), <fpage>1860</fpage>&#x02013;<lpage>1867</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.27872</pub-id>.<pub-id pub-id-type="pmid">23015160</pub-id>
</mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="weblink" id="cit34"><source>Multifunctional magnetic
nanoparticles for controlled release of
anticancer drug, breast cancer cell targeting, MRI/flu&#x000b7;&#x000b7;&#x000b7;</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ouci.dntb.gov.ua/en/works/4YXq1w67/">https://ouci.dntb.gov.ua/en/works/4YXq1w67/</uri> (accessed 2024&#x02013;03&#x02013;25).</mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Nabavinia</surname><given-names>M. S.</given-names></name>; <name><surname>Gholoobi</surname><given-names>A.</given-names></name>; <name><surname>Charbgoo</surname><given-names>F.</given-names></name>; <name><surname>Nabavinia</surname><given-names>M.</given-names></name>; <name><surname>Ramezani</surname><given-names>M.</given-names></name>; <name><surname>Abnous</surname><given-names>K.</given-names></name>
<article-title>Anti-MUC1 Aptamer: A Potential Opportunity
for Cancer Treatment</article-title>. <source>Med. Res. Rev.</source>
<year>2017</year>, <volume>37</volume> (<issue>6</issue>), <fpage>1518</fpage>&#x02013;<lpage>1539</lpage>. <pub-id pub-id-type="doi">10.1002/med.21462</pub-id>.<pub-id pub-id-type="pmid">28759115</pub-id>
</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Kang</surname><given-names>W. J.</given-names></name>; <name><surname>Lee</surname><given-names>J.</given-names></name>; <name><surname>Lee</surname><given-names>Y. S.</given-names></name>; <name><surname>Cho</surname><given-names>S.</given-names></name>; <name><surname>Ali</surname><given-names>B. A.</given-names></name>; <name><surname>Al-Khedhairy</surname><given-names>A. A.</given-names></name>; <name><surname>Heo</surname><given-names>H.</given-names></name>; <name><surname>Kim</surname><given-names>S.</given-names></name>
<article-title>Multimodal
Imaging Probe for Targeting Cancer Cells
Using uMUC-1 Aptamer</article-title>. <source>Colloids Surf. B Biointerfaces</source>
<year>2015</year>, <volume>136</volume>, <fpage>134</fpage>&#x02013;<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1016/j.colsurfb.2015.09.004</pub-id>.<pub-id pub-id-type="pmid">26387066</pub-id>
</mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Zhao</surname><given-names>H.</given-names></name>; <name><surname>Richardson</surname><given-names>R.</given-names></name>; <name><surname>Talebloo</surname><given-names>N.</given-names></name>; <name><surname>Mukherjee</surname><given-names>P.</given-names></name>; <name><surname>Wang</surname><given-names>P.</given-names></name>; <name><surname>Moore</surname><given-names>A.</given-names></name>
<article-title>uMUC1-Targeting
Magnetic Resonance
Imaging of Therapeutic Response in an Orthotropic Mouse Model of Colon
Cancer</article-title>. <source>Mol. Imaging Biol.</source>
<year>2019</year>, <volume>21</volume> (<issue>5</issue>), <fpage>852</fpage>&#x02013;<lpage>860</lpage>. <pub-id pub-id-type="doi">10.1007/s11307-019-01326-5</pub-id>.<pub-id pub-id-type="pmid">30793239</pub-id>
</mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Martinez
de la Torre</surname><given-names>C.</given-names></name>; <name><surname>Bennewitz</surname><given-names>M. F.</given-names></name>
<article-title>Manganese Oxide Nanoparticle Synthesis
by Thermal Decomposition of Manganese(II) Acetylacetonate</article-title>. <source>JoVE</source>
<year>2020</year>, <volume>160</volume>, <fpage>61572</fpage><pub-id pub-id-type="doi">10.3791/61572</pub-id>.</mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Snoderly</surname><given-names>H. T.</given-names></name>; <name><surname>Freshwater</surname><given-names>K. A.</given-names></name>; <name><surname>Martinez de la Torre</surname><given-names>C.</given-names></name>; <name><surname>Panchal</surname><given-names>D. M.</given-names></name>; <name><surname>Vito</surname><given-names>J. N.</given-names></name>; <name><surname>Bennewitz</surname><given-names>M. F.</given-names></name>
<article-title>PEGylation
of Metal Oxide Nanoparticles
Modulates Neutrophil Extracellular Trap Formation</article-title>. <source>Biosensors</source>
<year>2022</year>, <volume>12</volume> (<issue>2</issue>), <fpage>123</fpage><pub-id pub-id-type="doi">10.3390/bios12020123</pub-id>.<pub-id pub-id-type="pmid">35200382</pub-id>
</mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Arvizo</surname><given-names>R. R.</given-names></name>; <name><surname>Miranda</surname><given-names>O. R.</given-names></name>; <name><surname>Moyano</surname><given-names>D. F.</given-names></name>; <name><surname>Walden</surname><given-names>C. A.</given-names></name>; <name><surname>Giri</surname><given-names>K.</given-names></name>; <name><surname>Bhattacharya</surname><given-names>R.</given-names></name>; <name><surname>Robertson</surname><given-names>J. D.</given-names></name>; <name><surname>Rotello</surname><given-names>V. M.</given-names></name>; <name><surname>Reid</surname><given-names>J. M.</given-names></name>; <name><surname>Mukherjee</surname><given-names>P.</given-names></name>
<article-title>Modulating Pharmacokinetics, Tumor Uptake and Biodistribution
by Engineered Nanoparticles</article-title>. <source>PLoS One</source>
<year>2011</year>, <volume>6</volume> (<issue>9</issue>), <elocation-id>e24374</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0024374</pub-id>.<pub-id pub-id-type="pmid">21931696</pub-id>
</mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Zhou</surname><given-names>Z.</given-names></name>; <name><surname>Lu</surname><given-names>Z.-R.</given-names></name>
<article-title>Gadolinium-Based
Contrast Agents for Magnetic Resonance Cancer Imaging</article-title>. <source>WIREs Nanomedicine and Nanobiotechnology</source>
<year>2013</year>, <volume>5</volume> (<issue>1</issue>), <fpage>1</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1002/wnan.1198</pub-id>.<pub-id pub-id-type="pmid">23047730</pub-id>
</mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Khondee</surname><given-names>S.</given-names></name>; <name><surname>Chittasupho</surname><given-names>C.</given-names></name>; <name><surname>Tima</surname><given-names>S.</given-names></name>; <name><surname>Anuchapreeda</surname><given-names>S.</given-names></name>
<article-title>Doxorubicin-Loaded
Micelle Targeting MUC1: A Potential Therapeutic for MUC1 Triple Negative
Breast Cancer Treatment</article-title>. <source>CDD</source>
<year>2018</year>, <volume>15</volume> (<issue>3</issue>), <fpage>406</fpage>&#x02013;<lpage>416</lpage>. <pub-id pub-id-type="doi">10.2174/1567201814666170712122508</pub-id>.</mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="book" id="cit43"><person-group person-group-type="allauthors"><name><surname>Gavriil</surname><given-names>A.</given-names></name></person-group><source>Chimeric Antigen Receptor
(CAR) T-Cell Immunotherapy for MUC1-Positive Breast Cancer</source>; Doctor of Philosophy, <publisher-name>King&#x02019;s College London</publisher-name>, <year>2018</year>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://kclpure.kcl.ac.uk/portal/en/studentTheses/chimeric-antigen-receptor-car-t-cell-immunotherapy-for-muc1-posit">https://kclpure.kcl.ac.uk/portal/en/studentTheses/chimeric-antigen-receptor-car-t-cell-immunotherapy-for-muc1-posit</uri> (accessed 2025&#x02013;03&#x02013;28).</mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name><surname>Aoki</surname><given-names>I.</given-names></name>; <name><surname>Takahashi</surname><given-names>Y.</given-names></name>; <name><surname>Chuang</surname><given-names>K.-H.</given-names></name>; <name><surname>Silva</surname><given-names>A. C.</given-names></name>; <name><surname>Igarashi</surname><given-names>T.</given-names></name>; <name><surname>Tanaka</surname><given-names>C.</given-names></name>; <name><surname>Childs</surname><given-names>R. W.</given-names></name>; <name><surname>Koretsky</surname><given-names>A. P.</given-names></name>
<article-title>Cell Labeling for
Magnetic Resonance Imaging with the T1 Agent Manganese Chloride</article-title>. <source>NMR in Biomedicine</source>
<year>2006</year>, <volume>19</volume> (<issue>1</issue>), <fpage>50</fpage>&#x02013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1002/nbm.1000</pub-id>.<pub-id pub-id-type="pmid">16411253</pub-id>
</mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name><surname>Le
Fur</surname><given-names>M.</given-names></name>; <name><surname>Moon</surname><given-names>B. F.</given-names></name>; <name><surname>Zhou</surname><given-names>I. Y.</given-names></name>; <name><surname>Zygmont</surname><given-names>S.</given-names></name>; <name><surname>Boice</surname><given-names>A.</given-names></name>; <name><surname>Rotile</surname><given-names>N. J.</given-names></name>; <name><surname>Ay</surname><given-names>I.</given-names></name>; <name><surname>Pantazopoulos</surname><given-names>P.</given-names></name>; <name><surname>Feldman</surname><given-names>A. S.</given-names></name>; <name><surname>Rosales</surname><given-names>I. A.</given-names></name>; <name><surname>How</surname><given-names>I. D. A. L.</given-names></name>; <name><surname>Izquierdo-Garcia</surname><given-names>D.</given-names></name>; <name><surname>Hariri</surname><given-names>L. P.</given-names></name>; <name><surname>Astashkin</surname><given-names>A. V.</given-names></name>; <name><surname>Jackson</surname><given-names>B. P.</given-names></name>; <name><surname>Caravan</surname><given-names>P.</given-names></name>
<article-title>Gadolinium-Based Contrast Agent Biodistribution
and Speciation in Rats</article-title>. <source>Radiology</source>
<year>2023</year>, <volume>309</volume> (<issue>1</issue>), <elocation-id>e230984</elocation-id><pub-id pub-id-type="doi">10.1148/radiol.230984</pub-id>.<pub-id pub-id-type="pmid">37874235</pub-id>
</mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name><surname>Kim</surname><given-names>T.</given-names></name>; <name><surname>Momin</surname><given-names>E.</given-names></name>; <name><surname>Choi</surname><given-names>J.</given-names></name>; <name><surname>Yuan</surname><given-names>K.</given-names></name>; <name><surname>Zaidi</surname><given-names>H.</given-names></name>; <name><surname>Kim</surname><given-names>J.</given-names></name>; <name><surname>Park</surname><given-names>M.</given-names></name>; <name><surname>Lee</surname><given-names>N.</given-names></name>; <name><surname>McMahon</surname><given-names>M. T.</given-names></name>; <name><surname>Quinones-Hinojosa</surname><given-names>A.</given-names></name>; <name><surname>Bulte</surname><given-names>J. W. M.</given-names></name>; <name><surname>Hyeon</surname><given-names>T.</given-names></name>; <name><surname>Gilad</surname><given-names>A. A.</given-names></name>
<article-title>Mesoporous Silica-Coated
Hollow Manganese Oxide Nanoparticles as Positive T1 Contrast Agents
for Labeling and MRI Tracking of Adipose-Derived Mesenchymal Stem
Cells</article-title>. <source>J. Am. Chem. Soc.</source>
<year>2011</year>, <volume>133</volume>, <fpage>2955</fpage>&#x02013;<lpage>2961</lpage>. <pub-id pub-id-type="doi">10.1021/ja1084095</pub-id>.<pub-id pub-id-type="pmid">21314118</pub-id>
</mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name><surname>Qiu</surname><given-names>K.</given-names></name>; <name><surname>Seino</surname><given-names>R.</given-names></name>; <name><surname>Han</surname><given-names>G.</given-names></name>; <name><surname>Ishiyama</surname><given-names>M.</given-names></name>; <name><surname>Ueno</surname><given-names>Y.</given-names></name>; <name><surname>Tian</surname><given-names>Z.</given-names></name>; <name><surname>Sun</surname><given-names>Y.</given-names></name>; <name><surname>Diao</surname><given-names>J.</given-names></name>
<article-title>De Novo Design of A
Membrane-Anchored Probe for Multidimensional Quantification of Endocytic
Dynamics</article-title>. <source>Adv. Healthcare Mater.</source>
<year>2022</year>, <volume>11</volume> (<issue>8</issue>), <elocation-id>2102185</elocation-id><pub-id pub-id-type="doi">10.1002/adhm.202102185</pub-id>.</mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal" id="cit48"><name><surname>Hu</surname><given-names>Y.-B.</given-names></name>; <name><surname>Dammer</surname><given-names>E. B.</given-names></name>; <name><surname>Ren</surname><given-names>R.-J.</given-names></name>; <name><surname>Wang</surname><given-names>G.</given-names></name>
<article-title>The Endosomal-Lysosomal
System: From Acidification and Cargo Sorting to Neurodegeneration</article-title>. <source>Transl Neurodegener</source>
<year>2015</year>, <volume>4</volume>, <fpage>18</fpage><pub-id pub-id-type="doi">10.1186/s40035-015-0041-1</pub-id>.<pub-id pub-id-type="pmid">26448863</pub-id>
</mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal" id="cit49"><name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Wu</surname><given-names>C.</given-names></name>; <name><surname>Hou</surname><given-names>P.</given-names></name>; <name><surname>Zhang</surname><given-names>M.</given-names></name>; <name><surname>Xu</surname><given-names>K.</given-names></name>
<article-title>One-Pot Preparation
of Hydrophilic Manganese Oxide Nanoparticles as T1 Nano-Contrast Agent
for Molecular Magnetic Resonance Imaging of Renal Carcinoma in Vitro
and in Vivo</article-title>. <source>Biosens. Bioelectron.</source>
<year>2018</year>, <volume>102</volume>, <fpage>1</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.bios.2017.10.047</pub-id>.<pub-id pub-id-type="pmid">29101783</pub-id>
</mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal" id="cit50"><name><surname>Hu</surname><given-names>X.</given-names></name>; <name><surname>Ji</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>M.</given-names></name>; <name><surname>Miao</surname><given-names>F.</given-names></name>; <name><surname>Ma</surname><given-names>H.</given-names></name>; <name><surname>Shen</surname><given-names>H.</given-names></name>; <name><surname>Jia</surname><given-names>N.</given-names></name>
<article-title>Water-Soluble
and Biocompatible MnO@PVP Nanoparticles for MR Imaging
In Vitro and In Vivo</article-title>. <source>Journal of Biomedical
Nanotechnology</source>
<year>2013</year>, <volume>9</volume> (<issue>6</issue>), <fpage>976</fpage>&#x02013;<lpage>984</lpage>. <pub-id pub-id-type="doi">10.1166/jbn.2013.1602</pub-id>.<pub-id pub-id-type="pmid">23858961</pub-id>
</mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal" id="cit51"><name><surname>Fahrni</surname><given-names>C. J.</given-names></name>
<article-title>Biological
Applications of X-Ray Fluorescence Microscopy: Exploring the Subcellular
Topography and Speciation of Transition Metals</article-title>. <source>Curr. Opin. Chem. Biol.</source>
<year>2007</year>, <volume>11</volume> (<issue>2</issue>), <fpage>121</fpage>&#x02013;<lpage>127</lpage>. <pub-id pub-id-type="doi">10.1016/j.cbpa.2007.02.039</pub-id>.<pub-id pub-id-type="pmid">17353139</pub-id>
</mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal" id="cit52"><name><surname>Heimler</surname><given-names>K.</given-names></name>; <name><surname>Gottschalk</surname><given-names>C.</given-names></name>; <name><surname>Vogt</surname><given-names>C.</given-names></name>
<article-title>Confocal Micro X-Ray Fluorescence
Analysis for the Non-Destructive Investigation of Structured and Inhomogeneous
Samples</article-title>. <source>Anal Bioanal Chem.</source>
<year>2023</year>, <volume>415</volume> (<issue>21</issue>), <fpage>5083</fpage>&#x02013;<lpage>5100</lpage>. <pub-id pub-id-type="doi">10.1007/s00216-023-04829-x</pub-id>.<pub-id pub-id-type="pmid">37482571</pub-id>
</mixed-citation></ref></ref-list></back></article>